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Much has yet to be understood about the role of specific families of T 
lymphocytes in the post human hematopoietic stem cell (HSC) transplant environment. 
Prior work in the field has identified T cells based upon the expression of their T cell 
receptor beta variable regions (TCRBV). In this investigation we developed a 
comprehensive panel of oligonucleotides that can be used to determine the expression 
of all 91 alleles of the human TCRBV regions using real time PCR technology. 
Application of this technology to peripheral blood samples collected weekly from 
allogeneic peripheral blood stem cell transplant patients yielded the following findings: 
(1) specific TCRBV families are associated with the reactivation of cytomegalovirus 
(CMV) post HSC transplant with many of these same TCRBV families also being 
associated with the occurrence of GVHD, (2) the TCRBV repertoire engrafts in the 
recipient with a profile more similar to that found in the donor as opposed to that found 
in the recipient prior to transplant, and (3) the similar immunosuppressive agents, 
cyclosporin A (CSA) and tacrolimus (FK506), differentially alter the TCRBV repertoire 
with their administration, a difference which can not be attributed to a divergent 
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REVIEW OF LITERATURE 
1 
I. The History of Hematopoietic Stem Cell Transplantation 
Many advancements in the field of hematopoietic stem cell transplantation were 
borne from the seemingly unrelated birth of nuclear technologies. With the development 
of atomic technologies and the potential of nuclear warfare, the effects of irradiation on 
biological systems became an area of imminent interest 1. This resulted in a series of 
experiments conducted over the past fifty years and has greatly increased our 
understanding of hematopoietic stem cell transplant and the immunological 
mechanisms that are so critical to its success.  
The modern epoch of bone marrow transplantation was pioneered by Lorenz in 
1951 when he demonstrated that mice could be protected against lethal irradiation by 
intravenous infusion of bone marrow 2. This discovery quickly brought about the notion 
that hematological malignancies could potentially be cured through irradiation and 
subsequent marrow grafting. Barnes, et al., showed that murine leukemia could be 
successfully treated using sub-lethal doses of irradiation followed by the infusion of 
healthy marrow 3. The following year, the first reports detailing similar clinical trials in 
humans were made, describing the immediate rescuing from radiation-induced 
pancytopenia in cancer patients by marrow infusion 4,5. In 1959, Mathe et al., attempted 
bone marrow transplantation in humans on a larger scale when they tried to rescue six 
victims of a radiation accident in Vinca, Yugoslavia, by transplanting allogeneic bone 
marrow 6. This group continued trying to use bone marrow transplantation as treatment 
for hematologic malignant conditions, however, it was not until 1963 that they reported 
the first case of a patient surviving beyond a year. While this patient remained leukemia-
free, severe graft-versus-host disease (GVHD) reactions were documented, the first of 
such, and the patient succumbed to infection 20 months post-transplant 7. 
 
II. Types of  Hematopoietic Stem Cell Transplantation 
There are three primary types of hematopoietic stem cell transplants depending 
upon the stem cell source and the identity of the donor. These are termed autologous, 
allogeneic, and syngeneic transplants. The first type, autologous transplant, describes 
the process where an individual serves as his/her own stem cell source. In order for an 
autologous stem cell transplant to be successful, the individual’s marrow must be 
virtually disease free prior to harvesting. An example of the use of this type of transplant 
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is one in which a patient must undergo intensive treatment directed at his/her tumor, 
which, as a consequence, would inadvertently cause destruction to his/her 
hematopoietic system. After the high-dose tumor therapy, the patient can then be 
infused with the previously collected stem cells to rescue his/her hematopoietic system. 
Autologous transplants are now most frequently used for hematologic malignancies 
such as lymphomas. Advantages to autologous transplantations are that there is no 
need to locate a suitable stem cell donor as well as a decreased risk of treatment-
related mortality. Such transplants, however, have a risk of tumor cell contamination in 
the graft. Additionally, autologous transplants cannot be used in the treatment of 
inherited non-malignant hematopoietic diseases or acquired marrow failure states, such 
as aplastic anemia 8.   
The second major type of hematopoietic stem cell transplant, termed an 
allogeneic transplant, is one in which the stem cell donor is separate from the recipient. 
The donor must be genetically matched to the recipient but the two can either be related 
or unrelated. Advantages of this type of transplant are that there is a low risk of the graft 
being contaminated with malignant cells and it can successfully be used in treating both 
malignant and non-malignant diseases of the hematopoietic system. An additional 
advantage to allogeneic transplant is the possible destruction of residual recipient tumor 
cells by the infused donor-derived cells, an occurrence termed graft-versus-tumor effect. 
Despite these advantages, however, there is often great difficulty in finding an 
appropriate donor and there is a greater increase, compared to autologous transplants, 
of post-transplant complications, such as graft-versus-host disease 8. 
The third major type of hematopoietic stem cell transplant is one in which the 
donor and recipient are genetically identical, such as the case that occurs when the 
recipient and donor are identical twins, and is termed a syngeneic transplant. Post 
transplant complications tend to be diminished in this setting, compared to a non-
identical allogeneic transplant, but while the majority of patients may have a sibling, it is 
relatively uncommon for the sibling to be an identical twin 8.  
Traditionally, hematopoietic stem cells (HSC) have been harvested from bone 
marrow through extraction at the iliac crests. Recent advancements in transplantation 
technology, though, have permitted the mobilization of hematopoietic stem cells from 
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the bone marrow environment to the peripheral circulation through the use of growth 
factors such as granulocyte colony stimulating factor (G-CSF) 9-13. HSC comprise only a 
small fraction of the total number of cells in the bone marrow, with a rate of 
approximately one HSC/10,000 total bone marrow cells and the number of HSC 
circulating in the peripheral blood is an exceedingly rare event 14. After G-CSF 
administration, however, the frequency of HSC in the peripheral blood is increased two 
to five-fold greater than that found in the bone marrow 15. Mobilized HSC can then be 
harvested from the peripheral blood by a pheresis procedure. A dose of at least five 
million HSC/kg recipient weight has been reported to be the ideal dose to achieve 
engraftment 16.  
While multiple collections may be required in order to achieve the necessary 
number of stem cells for transplant using the G-CSF mobilization technique, there is a 
low toxicity profile associated with G-CSF administration in humans 10-13. The side 
effects are generally limited to bone pain and general influenza-like symptoms and there 
have been no documented reports of termination of G-CSF administration to healthy 
donors due to its side effects. Thrombocytopenia, or the reduction in platelet number, is 
frequently observed post-pheresis in G-CSF mobilized donors. This reduction, as well 
as any bone discomfort, is generally reversed within 48 hours of cessation of drug 
administration. On the other hand, while bone marrow harvests require no mobilization 
therapies and can often be done in a single one-day collection, the pain associated with 
bone marrow harvests may take 2 to 4 weeks to subside 17,18. In addition, various 
studies have reported a decreased time for reconstitution of the immune system, less 
transplant-related toxicities and mortalities, and a decreased rate of GVHD occurrence 
in peripheral blood stem cell recipients compared to bone marrow recipients 19-23.  
The benefits of peripheral blood stem cell harvesting, compared to bone marrow 
harvesting, have resulted in peripheral blood stem cell transplantation becoming much 
more frequently used compared to bone marrow transplantation. HSC have also been 
collected from umbilical cord blood and used successfully in allogeneic transplantation. 
While cord blood HSC have decreased alloreactive potential compared to their 
counterparts isolated from more mature donors, cord blood stem cells exhibit a delayed 
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reconstitution of the hematopoietic system, thereby limiting their usage in hematopoietic 
stem cell transplantation 24-30.   
In allogeneic transplants the conditioning regimen the recipient receives prior to 
transplant is highly dependent upon the type of disease the patient has as well as how 
aggressively it behaves 31. There are three main objectives to the treatment. The 
primary objective is to eradicate the underlying hematological disease in the recipient. 
The second objective is to suppress the recipient’s immune system to decrease the risk 
of the recipient rejecting the donor’s stem cells. The third objective in using a 
conditioning regimen pre-transplant is to create space in which the donor’s stem cells 
can engraft and growth can be accommodated 32. While the amount of time required for 
immune reconstitution post hematopoietic stem cell transplant varies depending upon 
parameters such as the type of transplant, conditioning regimens, and 
immunosuppressive therapies, CD8+ T cell counts tend to recover to normal values 
within the first month post transplant with a prolonged deficiency of CD4+ T cell counts 
often seen six to twelve months post transplant, leading to the characteristic inversion of 
the CD4:CD8 ratio observed post transplant 33-37.    
 
III. HLA 
Based on experiments initially performed in mice 38 antigenic principles 
underlying cellular transplantation began to be established. Such experiments led to the 
recognition of what became termed the H2 transplantation antigen system 39 in mice 
and the HLA system in humans 40. The human leukocyte antigen (HLA), also termed the 
major histocompatibility complex (MHC) forms a complex which is expressed on the 
cellular surface. The principle function of this molecule is to present peptides (from 
either self or non-self origin) to T lymphocytes, a vital component to the immune system. 
By doing so, the T lymphocytes are able to distinguish self versus non-self. An 
illustration of this principle is afforded by examining what occurs during a viral infection: 
if a cell is infected with a virus, pieces of viral proteins (non-self) are loaded into the 
MHC molecule and presented on the surface of the infected cell. The interaction of a 
circulating T cell with this (non-self) MHC molecule can activate the T cell, causing it to 
destroy the infected cell, thereby limiting the spread of infection. The same is true in the 
setting of transplantation. T cells in the donor graft can recognize cells within the 
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recipient’s body as non-self, eliciting devastating immune reactions. This is the premise 
of a serious post-transplant complication called graft-versus-host disease (GVHD) 41.  
There are three classes of HLA (or MHC) genes, termed class I, class II, and 
class III genes, with all three being located on chromosome 6 in humans. The names 
HLA-A, HLA-B, and HLA-C are given to the human MHC class I genes while the MHC 
class II genes are identified as HLA-DR, HLA-DP, and HLA-DQ. The products of these 
MHC class I genes are expressed on the surface of nearly all cells within the human 
body while the expression of the MHC class II genes is restricted to antigen presenting 
cells and thymic epithelium. Classically, MHC class I proteins present endogenous 
antigen (or peptide) to CD8+ T cells while the MHC class II proteins present exogenous 
antigen (or peptide) to CD4+ T cells. The final class of genes, those located within the 
MHC class III region, encode various immunologically relevant proteins such as 
complement and the tumor necrosis factor cytokines 42.  
Figure 1: Gene structure of the human major histocompatibiltiy complex (MHC) 
 
 
The HLA genes are expressed in a co-dominant fashion and are highly 
polymorphic 43. In terms of their importance in hematopoietic stem cell transplantation, 
matching at the MHC class I HLA-A and HLA-B loci was given priority as previously 
there had been a lack of reagents available to accurately determine the HLA-C 
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genotype. Due to the advancements of molecular biology, however, such discrimination 
is now possible. In fact, recent reports have been made concerning the importance of 
HLA-C matching in hematopoietic stem cell transplantation 44-46. As it relates to the 
MHC class II molecules, allelic mismatching of the donor and recipient at the HLA-DR 
loci was the first to be shown to be associated with an increase in graft-versus-host 
disease reaction 47. The importance of HLA-DQ matching is also becoming more 
apparent 48. However, like its MHC class I counterpart (HLA-C), mismatching at the 
HLA-DQ locus has yet to become a basis for donor exclusion. The role of HLA-DP in 
transplantation has remained rather controversial and is also not typically evaluated 
when searching for an appropriate donor 49. In summary, the common practice of HLA 
matching in related donor and recipient has remained matching of the HLA-A, HLA-B, 
and HLA-DR loci, although typing of additional loci is commonly performed when an 
unrelated donor is being considered. Likewise, HLA matching is typically performed 
using serological methods when the donor is related and by molecular analyses when 
the donor and the recipient are not related.  
 
IV. T Cells 
On the converse side of the MHC molecule is the T cell, whose interaction with 
the MHC molecule is mediated 
through the T cell receptor 
(TCR). T lymphocytes originate 
in the bone marrow from a 
lymphoid progenitor cell and 
migrate to the thymus as 
immature cells. The thymus 
provides a unique 
microenvironment in which the 
T lymphocyte rearranges its 
receptor genes (chromosome 
14, TCR alpha genes and 
chromosome 7, TCR beta 
Figure 2: T cell receptor (TCR) gene rearrangement 
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genes 50) and matures. T cell receptor (TCR) gene rearrangement occurs in the sub 
capsular region of the thymus with rearrangement of the heavy chain (or beta chain) 
genes occurring prior to rearrangement of the light chain (or alpha chain) genes. Within 
the T cell receptor beta chain locus, a diversity (D) segment is randomly paired with a 
joining (J) segment. This DJ unit is then rearranged with a variable (V) segment to form 
a VDJ segment. The constant (C) region exon is then spliced to the VDJ segment to 
generate the message, which is translated into the T cell receptor beta chain protein. 
Beta chain gene rearrangement is followed by rearrangement of the TCR alpha chain, 
which occurs in the same manner as for the heavy chain. However, as there is no 
diversity region in the light chain, rearrangement of the variable and joining segments is 
followed by the VJ pairing with a constant (C) segment 50-52.  
After the heavy and light chain rearrangements occur, the T cell begins to 
undergo maturation and moves deeper into the thymus. In the cortex of the thymus the 
immature cells undergo positive selection where only those developing cells that 
recognize antigens presented by self-MHC molecules can mature. Those T cells that do 
not recognize antigen in the context of a self-MHC molecule are deleted by apoptosis. 
As the positively selected thymocytes move into the cortico-medullary junction of the 
thymus they undergo negative selection where those that recognize self-antigens too 
well are deleted. Negative selection helps to remove auto-reactive T cells from the 
repertoire. Finally, those thymocytes that have survived both positive and negative 
selection exit through the medulla of the thymus and enter the peripheral circulation 
where they traffic through secondary lymphoid organs monitoring the body through T 
cell receptor:peptide:MHC interactions 50-52. The significance of the wide variety of MHC 
molecules (more than fifty alleles at each of the HLA-A, HLA-B, and HLA-DR loci 
identified 53) and possible TCR rearrangements (24 million 54) is critical to the ability of 
an individual’s immune system to respond to a wide variety of pathogens.  
With an understanding of the molecular interaction between the MHC molecule 
and the TCR, the importance of T cells in the post hematopoietic stem cell transplant 
setting becomes clearer. Investigations into these reactions and their role in graft 




Hematopoietic stem cell transplant offers patients a potential for recovery from 
otherwise lethal conditions. However, associated with this possibility is the threat of 
graft-versus-host disease (GVHD), a reaction where the transplant recipient’s tissue is 
attacked and destroyed by the infused donor cells. GVHD-like reactions have been 
observed in mice that had been treated with allogeneic marrow after irradiation. While 
these mice recovered from their marrow ablation, the mice died from what was termed 
“secondary disease”, now known as graft-versus-host disease 41, a condition marked by 
weight loss, diarrhea, and liver and skin changes 56,57.   
In 1957, such observations in mice led Billingham to establish criteria essential 
for the development of graft-versus-host disease. The first of these criteria is that the 
graft must contain immunologically competent cells. Secondly, the recipient of this graft 
must not be able to mount an immune response against these transplanted cells, which 
would lead to their ultimate destruction. Finally, the recipient must also express antigens 
that are not present in the donor graft 58.  
Billingham’s first requirement was further understood when in 1962, Gowen 
identified the cells responsible for GVHD as small lymphocytes 59, but it was not until 25 
years after these first observations that the “immunologically competent cells” were 
actually identified as T lymphocytes 60. In 1986 Kernan demonstrated a direct 
correlation between the severity of GVHD and the number of donor T cells transfused 
67. Attempts have been made to T-cell deplete grafts (ex vivo) prior to transplant which 
decreases the risk of GVHD, and to then use “add-backs” of donor lymphocytes post 
transplant in order to promote the graft-versus-tumor effect 61-79. The complete removal 
of T cells from the graft, however, has been shown to cause an increase in graft failure 
and is, therefore, not a practical option 80,81.  
Billingham’s second requirement of the recipient being devoid of immuno-
competent cells is typically not of great concern in hematopoietic stem cell 
transplantation as recipients classically receive intense immunosuppressive treatments 




With the discovery of the MHC genes and the role that they play in 
transplantation, an increased understanding of Billingham’s third requirement was 
achieved. As previously discussed, these MHC molecules are necessary for activation 
of T cells, in both autologous and allogeneic transplant settings 85. In allogeneic 
transplants the matching of the donor and recipient’s HLA antigens is one of the 
foremost criteria in selecting an appropriate hematopoietic stem cell donor. It has been 
observed, though, that even with matching of these antigens, GVHD reactions can still 
occur 86 and have been attributed to what have been termed minor histocompatibility 
antigens.  
Minor histocompatibility antigens, or mHA, have been defined as a non-MHC 
locus that can elicit allogeneic tissue rejection 87,88. Minor histocompatibility antigens are 
inherited and are not necessarily in close proximity to the HLA genes 89. It has been 
shown that certain MHC present specific mHA 90,91 and specific mHA elicit responses 
from specific TCRBV 92. There have been seventeen minor histocompatibility antigens 
identified thus far, with the expression of twelve of these being restricted to cells of the 
hematopoietic lineage 91,93,94. At the present time, while it is known that mHA differences 
can contribute to GVHD, it is difficult to predict the outcome of a hematopoietic stem cell 
transplant based upon identification of these minor histocompatibility antigens 95,96. 
One model describes the development of GVHD as occurring in two phases: the 
afferent and efferent phases. The afferent phase consists of the damage incurred to the 
recipient both by the pre-transplant conditioning regimens (chemotherapy/radiation) as 
well as by the activation of the donor T cells. It has been shown that the conditioning 
regimens cause damage to and activate tissues within the recipient, including the tissue 
of the gastrointestinal tract as well as the liver 97-100,. Such damage results in the release 
of LPS and inflammatory cytokines, such as IL-1, tumor necrosis factor (TNF) alpha, 
and interferon (IFN) gamma, from the activated tissues which causes the subsequent 
activation of host antigen presenting cells 23,101-112. Further complicating these 
circumstances is the fact that LPS and IFN gamma can act in a synergistic fashion, 
additionally increasing the levels of pro-inflammatory cytokines such as TNF alpha 113. 
In addition it has been shown that the administration of antagonists to LPS, as well as to 
the receptors for these inflammatory cytokines, has ameliorated the effects of GVHD 
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103,105,110,114. The important role of LPS in GVHD is also supported by the observation 
that pathogen-free mice have reduced incidence of GVHD after allogeneic transplant 
115,116.  
The efferent stage of GVHD is comprised of the actual destruction of the 
recipient tissues by activated T lymphocytes responding to allogeneic antigens 117. A 
combination of the afferent and efferent stages contribute to the devastation seen in 
GVHD.  
GVHD can present itself in two forms, acute and chronic. Acute GVHD presents 
within the first 100 days post-transplant whereas the chronic form appears post day 
100. The pathology of the two forms show similarities, however 41.  
There are four grades of acute GVHD: I-IV, with IV being the most severe. While 
the development of GVHD grade I or II is associated with an increased risk of 
developing GVHD grade III or IV, little morbidity is associated with GVHD grade I. 
However, much greater levels of morbidity are seen with the progression of GVHD to 
grades II and III, and grade IV GVHD represents a life threatening condition 41.     
In acute GVHD the primary target organs are the skin, gastrointestinal tract, and 
liver, with the skin being the most easily observed and often first diagnosed target 
organ. In the skin, GVHD presents as erythema and rash, commonly located on the 
palms and soles initially, but can spread to involve the rest of the body. In severe 
situations, the skin may actually become desquamated (grade IV). In terms of its effect 
on the gastrointestinal tract and liver functioning, symptoms include nausea, vomiting, 
diarrhea and hyperbilirubinemia. In each instance, with increased severity of these 
symptoms or worsening laboratory findings, the higher the grade of GVHD 41.  
 
VI. Immune Suppression 
Allogeneic hematopoietic stem cell transplant recipients are routinely given 
immunosuppressive agents to facilitate engraftment and decrease the risk of developing 
GVHD post transplant. Cyclosporin A (CSA), tacrolimus (FK506), and methotrexate, are 
examples of such agents. CSA and FK506 have similar mechanisms of action, which is 
to bind to cyclophilin or FK binding protein (FKBP), respectively; the resulting drug-
protein complexes inhibit calcineurin activity 118-128. The protein calcineurin is directly 
involved in the transcription of cytokines, such as IL-2. Through the administration of 
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CSA or FK506 it is possible to inhibit expansion of allo-reactive T cells and their 
reactions post transplant. CSA and FK506 treatment is begun one day before transplant 
(d-1) and continues throughout the post transplant period.  
The mechanism of methotrexate, pulses of which the patients receive as part of 
standard GVHD prophylaxis, is through the inhibition of dihydrofolate reductase, the 
enzyme responsible for purine and pyrimidine synthesis, which leads to the suppression 
of T cell activation and adhesion molecule expression 129. Methotrexate infusions are 
administered on days 1, 3, 6, and 11 post-transplant as standard GVHD prophylaxis.  
While immunosuppressive agents such as these help to prevent graft rejection 
and GVHD, such suppression makes it difficult for the patient to mount immune 
responses against invading pathogens and also makes the patient more susceptible to 
the reactivation of latent infections, such as cytomegalovirus.         
 
VII. Infection Susceptibility 
After hematopoietic stem cell transplant patients are highly susceptible to 
bacterial, viral, and fungal infections. To decrease the risk of overwhelming infections 
post-transplant, patients receive prophylactic antibiotics. Use of prophylactic anti-fungal 
agents, such as fluconozole, decreases the occurrence of fungal infections, but in spite 
of the use of prophylactic antifungal therapy, patients can develop fungal infections 
including those attributed to Candida and Aspergillus species 130. Examples of bacterial 
infections that are commonly observed post transplant include both gram positive 
(Staphyloccocus, Enterococcus,  Clostridium, and Corynebacterium) and gram negative 
bacteria (Haemophilus and Escherichia). As previously mentioned, reactivation of latent 
cytomegalovirus (CMV) is a common occurrence post hematopoietic stem cell 
transplant 130.  
 
VIII. Identification of T Cells Involved in GVHD Through TCRBV Analysis 
In graft-versus-host disease (GVHD), the donor T cells recognize the host 
(recipient) MHC molecule as foreign, causing destruction of the cells expressing the 
allo-reactive molecule. Such reactions are also important in the recipient’s defense 
against reactivation of latent infections such as CMV. Since it is the variable region of 
the TCR that is in intimate contact with the MHC molecule, determining what specific 
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variable families of T cells can be linked to the destructive effects of GVHD has been a 
focus of investigation 131-143. Due to the prior lack of standardized nomenclature for TCR 
gene families, classification of the variable region data has become complicated 
because different investigators named the same family different names and, conversely, 
different families were named the same. To resolve this classification dilema an 
international team was formed to assign consistent and systematic names to all of the 
TCR variable gene segments. Bernhard Arden published the results in 1995 144. At 
present, there are 32 functional alpha TCR variable families in humans with 69 
subfamily members and 25 functional beta TCR variable families in humans with 91 
subfamily members. As antibodies recognizing all of these TCR variable families are not 
available, an alternative approach is to use RT-PCR to evaluate the expression of the 
messages (mRNA) used to make these surface proteins. Primer panels previously 
designed to detect the wide range of TCR variable families do not, however, detect all of 
the TCR variable families outlined in the Arden paper 138,145-189, due to the unavailability 
of the classification system at the time of primer development or the labor-intensive task 
of developing and validating a truly complete primer panel.  
 
IX. Summary 
Since its early inception, bone marrow transplantation has been used to treat 
conditions ranging from exposure to a radiation accident in the late 1950s to treating 
conditions such as leukemia and lymphoma, aplastic anemia, as well as immune-
deficiency disorders such as congenital neutropenia in the twenty first century 6.  
Despite advancements in the field of hematopoietic stem cell transplantation, 
serious complications can still occur post transplant. These include the occurrence of 
GVHD, severely immune-suppressed states that can lead to reactivation of latent 
infections such as CMV, and therapeutic agent toxicities 13,130,190.  
If it is possible to determine prior to transplant the GVHD-causing T cells, those 
cells can be depleted or inhibited prior to blood or marrow infusion, thereby preventing 
the development of GVHD. Experiments performed in mice have demonstrated that 
when TCR variable families have been identified as being implicated in GVHD, those 
cells can be depleted prior to transplant, preventing development of a graft-versus-host 
reaction 191. In addition, those cells can be adoptively transferred into a lethally 
13 
irradiated host and initiate a graft-versus-host disease reaction 192. Should trials in 
humans yield such predictable results, blood and marrow transplantation could become 
a treatment modality with a much-decreased risk of morbidity and mortality and offer 
hope of a cure to more patients. 
 
X. Research Objectives 
The main objective of the work presented in this dissertation is to understand the 
role of specific groups of T cells after hematopoietic stem cell transplantation in 
humans. The importance of T cells post hematopoietic stem cell transplantation has 
long been recognized. There is a significant lack of understanding, though, as to the 
role specific T cells play in this setting. This project will determine the role of specific T 
cells, as identified by expression of their T cell receptor beta variable region, in certain 





1. Develop a methodology to accurately detect expression of all the human TCRBV 
families. Many previous investigations have detailed molecular based methods 
used to identify the various TCRBV families in humans. These reports fail to 
account for the standardized classification of the TCRBV genes by the World 
Health Organization and often leave specific subfamilies and alleles undetected. 
Serological methods, such as antibody staining, have also been employed by 
prior studies. This method, too, lacks the ability to detect all of the human TCRBV 
genes. We aimed to develop a modern molecular based method that can 
specifically detect all alleles of the human TCRBV repertoire.  
 
 
2. Utilizing technology developed in objective 1, determine the association of 




a. Graft-Versus-Host Disease (GVHD) 
GVHD is a common post hematopoietic stem cell transplantation 
complication and we aim to determine if specific families of T cells are 
associated with the occurrence of this condition.  
 
b. Cytomegalovirus (CMV) reactivation 
During the immune suppressed state post transplant, patients often 
experience reactivation of latent infections, such as CMV, which contribute 
additional complications to the recovery stage. GVHD and CMV have 
been linked to each other in previous reports. We aim to determine (1) 
what specific families of T cells are associated with reactivation of CMV 
post transplant and (2) if there is any overlap in the T cells associated with 
both GVHD and CMV.  
 
c. Immunosuppressive therapies Cyclosporin A (CSA) and tacrolimus (FK506)   
Immunosuppressive therapies, such as CSA and FK506, are administered 
post hematopoietic stem cell transplant to curtail the development of graft 
rejection and graft-versus-host disease. These agents target activated T 
cells through their suppression of IL-2 production. We aim to determine if 
the effects of these agents on the TCRBV repertoire is the same with both 
CSA and FK506.  
  
d. Correlation of engraftment profiles to baseline donor and recipient samples  
It is not known whether the identity of the engrafting TCRBV repertoire is 
more like that found in the recipient prior to transplant or if it mimics that 
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Comprehensive gene expression analysis of the T cell receptor repertoire of an 
individual can be very useful in evaluating the immune response in a variety of 
conditions. Antibody based analysis methods can detect approximately sixty percent of 
the human T cell receptor beta variable (TCRBV) proteins, while gene expression 
analysis, primarily through employment of the polymerase chain reaction (PCR), has 
had somewhat greater success in the detection of additional TCRBV families. Many of 
these previous PCR methods, however, have been unable to detect all 91 alleles of the 
human TCRBV genes. This is primarily due to either deficiencies in the amplification of 
all of the variable beta families, subfamilies, and alleles, or the prior lack of a systematic 
classification of the TCR variable family gene segment sequences. We describe here a 
real time reverse-transcription polymerase chain reaction based method, which allows 
efficient automation and integration of amplification, detection, and analysis with 
sequence specific detection of all T cell receptor beta variable gene families, 
subfamilies, and alleles. This method, which in itself contributes significant 
improvements over existing technologies through its comprehensiveness and efficiency, 
also functions independently of variables such as sample source and sample 
processing and has the ability to run on multiple real-time PCR platforms, affording one 
the implementation of personal preferences. 
 
 INTRODUCTION  
 
T cells constitute a component of the immune system that is able to distinguish 
“self” versus “non-self”. This is accomplished through the interaction of their T cell 
receptor (TCR) with the antigen:major histocompatibility complex (a:MHC) expressed on 
the surface of cells. The αβ T cell receptor is a heterodimer, one component of which is 
a beta (B) chain, consisting of both a variable (V) and a constant (C) region. It is the 
variable region of the chain that directly contacts the a:MHC, eliciting the T cell 
response. Each individual has multiple TCRBV gene segments (or families) allowing for 
the ability to respond to a large number of a:MHC complexes 1. 
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A primary way to analyze the T cell receptor repertoire in an individual is through 
the use of antibody-based methods. Antibody based analysis methods can detect 
approximately sixty percent of the human T cell receptor beta variable (TCRBV) 
proteins, while gene expression analysis, primarily through employment of the 
polymerase chain reaction (PCR) 2, has had somewhat greater success in the detection 
of additional TCRBV families. Many of these previous PCR methods, however, have 
been unable to detect all 91 alleles of the human TCRBV genes. Such a comprehensive 
PCR strategy, however, requires the usage of both uniform and systematic 
organizations of the TCRBV genetic sequences. Such a TCRBV classification system 
was established by the World Health Organization (WHO) and has resulted in the 
identification of 25 different functional B variable families (with 91 subfamily and allele 
members total)3. Based on the WHO classification of the TCRBV families, two 
sequences reside within the same family if there is at least 50% homology between the 
two sequences. Subfamily members share at least 75% sequence homology and alleles 
of a given TCRV gene differ at no more than a few residues 3. 
Previous attempts at establishing PCR-based methods to evaluate the 
expression of all members of the TCR families have not taken into account the new 
WHO systematic classification or the wide variety of subfamilies and alleles that exist for 
many of the variable families 4-49. When possible, such references were consulted for 
potential primer sequences. However, many of those sequences did not satisfy the 
requirements of amplifying all of the various subfamilies and alleles within a given 
variable family or they inadvertently cross-amplified the sequence of a closely related 
variable family. The generation of a comprehensive panel of TCRBV primer sequences 
presented a significant challenge as the TCRBV families all share nearly 50% homology 
with each other and sequences designed to detect a specific family can inadvertently 
cross-amplify a closely related TCRBV family. We designed primers that will specifically 
detect all known alleles within the identified TCRBV families and, when possible, we 
designed a single primer to detect all alleles of a given TCRBV family, thereby 
improving on previous panels that required using multiple primer sequences to amplify 
multiple alleles of a given TCRBV family. In addition, some of the primer sequences 
from previous panels, while potentially meeting our stringent specificity requirements, 
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had a melting temperature that fell outside of our desired ten-degree melting range of 
55oC to 65oC, making it difficult to analyze expression of all of the TCRBV families in a 
single experiment with a single amplification cycling protocol. 
We describe here how we have established a complete panel of PCR primers 
that can be used with sequence specific real-time PCR methodology to evaluate the 
expression of all the TCRBV gene families, including all subfamily and allele members. 
The user has the flexibility of using many sample sources and processing methods, as 
well as benefiting from automated and integrated amplification, detection, and analysis 
in a gel free environment on a wide variety of real time PCR platforms. The technology 
can be applied to any area of study examining T cell biology, including autoimmunity, 
transplantation, cancer therapy, and infectious disease.   
 
MATERIALS AND METHODS  
 
Primer and Probe Development 
Primer sequences were developed using the TCRBV classification system 
described by Arden, et al. 3. Sequences were analyzed and potential primer sequences 
were evaluated for cross-reactivity using GenBank’s BLAST tool (National Center for 
Biotechnology Information, http://www.ncbi.nlm.nih.gov/BLAST/). Human 18S rRNA 
primers and TaqMan® probe were designed using Beacon Designer 2 software 
(PremierBiosoft International, Palo Alto, CA, USA). TaqMan® probes were analyzed for 
cross-reactivity using GenBank’s BLAST tool (National Center for Biotechnology 
Information).   
 
Peripheral Blood Samples 
A volume of ~20 mL of peripheral blood was collected, via venipuncture from 
individual healthy donors and from a hematopoietic stem cell transplant patient, into  
acid citrate dextrose VACUTAINER™ blood collection tubes (Becton Dickinson, 
Franklin Lakes, NJ, USA). Informed consent was obtained from participants after the 
nature and possible consequences of the study had been fully explained according to 
West Virginia University’s Internal Review Board guidelines. Buffy coat layers were 
isolated via centrifugation at 3300 rcf for 10 minutes. Contaminating red blood cells 
were removed by hypotonic lysis. 
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Flow Cytometric Analysis 
Peripheral blood composition was determined by light scatter profiling using a 
CELL-DYN 3500 (Abbott Diagnostics, Santa Clara, CA, USA). Additional classification 
of the lymphocyte population was performed by cell surface staining using antibodies 
specific to CD4 (Beckman Coulter, New York, NY, USA), at a volume of 20 µL antibody 
per 5 x 105 cells, CD8, and CD19 (Caltag Laboratories, Burlingame, CA, USA), both at 
antibody concentrations of 1 µg per 1 x 106 cells. Cells were blocked prior to antibody 
addition by incubating cells for five minutes at room temperature with human IgG at a 
concentration of 200 µg per 5 x 105 cells (Sigma Chemical Co., St. Louis, MO, USA). 
After antibody addition, cells were incubated 30 minutes in the dark at room 
temperature followed by a single wash with 1x PBS. The stained cells were then fixed in 
500 µL of 1% paraformaldehyde. All prepared samples were analyzed by flow 
cytometric analysis using a FACScan™ (Becton Dickinson), which had been calibrated 
using three color Calibrite™ Beads (Becton Dickinson) and FACSCOMP™ software 
(Becton Dickinson). For further lymphocyte analysis of CD19+, CD8+, and CD4+ 
expression 10,000 total events were collected for each sample. SSC and FSC data 
were acquired in the linear mode and the FL1, FL2, and FL3 parameters were collected 
logarithmically. Data analysis was performed using Windows Multiple Document 




Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent 
according to the manufacturer’s directions (Ambion, Austin, TX, USA). RNA was 
dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen 
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA 
according to the manufacturer’s recommendations using DNA-free™ (Ambion).  RNA 
purity and concentration was determined by standard 260nm:280nm spectrophotometric 
analysis using a Genesis 10UV Spectronic Unicam (Spectronic Instruments, Rochester, 




One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit 
(Qiagen, Valencia, CA, USA). Recommended reaction mixtures were scaled down to a 
total reaction volume of 20 µL using 0.04 µg RNA with the following primer and probe 
concentrations: 0.4 µM TCRBV primer (Biosource International, Camarillo, CA, USA), 
0.4 µM TCRBC primer (Biosource International), and 0.2 µM TCRBC TaqMan® probe, 5’ 
6-FAM, 3’ BHQ™-1 (Integrated DNA Technologies, Inc., Coralville, IA, USA). 18SrRNA 
control reactions were performed in parallel using 0.4 µM each of sense and anti-sense 
primers (Biosource International) and 0.2 µM 18SrRNA TaqMan® probe, 5’ 6-FAM, 3’ 
BHQ™-1 (Integrated DNA Technologies, Inc.).  
An iCycler™ (BioRad Laboratories, Hercules, CA, USA) was used for the RT and 
amplification cycles. RT was performed at 50oC for 60 minutes, max ramp speed, 
followed by an initial Taq DNA polymerase activation step of 15 minutes at 95oC, max 
ramp speed. A TouchDown PCR approach 50 was used with the following cycling 
conditions: denaturation for 15 seconds at 95oC, max ramp speed, annealing for 30 
seconds starting at 70oC decreasing by 2oC for 10 repeats, max ramp speed, and 
extension for 40 seconds at 72oC, min ramp speed. After this TouchDown of the 
annealing temperature, 50 cycles were performed as follows with the optical data 
collection occurring at the extension step: 15 seconds at 95oC (max ramp speed), 30 
seconds at 52oC (max ramp speed), and 40 seconds at 60oC (min ramp speed). 
Reactions were held at 4oC upon the conclusion of the run. Amplification efficiencies 
using cDNA dilutions were determined using the above described cycling protocol with 
the deletion of the reverse transcription cycle of 50oC for 60 minutes. 
 
cDNA isolation 
PCR products were electrophoresed on a 2% agarose gel using 20 µL PCR 
product and 4 µL tri-color 6X loading dye (Promega, Madison, WI, USA). Promega PCR 
marker was loaded into a control lane at the manufacturer’s specifications (Promega). 
Product bands were excised using the QIAquick® Gel Extraction Kit protocol according 
to the manufacturer’s instructions (Qiagen). cDNA purity and concentration was 
determined by standard 260nm:280nm spectrophotometric analysis using a Genesis 
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10UV Spectronic Unicam (Spectronic Instruments). cDNA dilutions were performed 
using ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen Corporation).  
 
Southern Blot Analysis 
Nucleic acid bands were transferred from the 2% agarose gel (described above) 
to BioBond™ Plus Nylon Membrane (Sigma Chemical Co.) using the Alkaline Southern 
Breeze™ Blotting Kit (Sigma Chemical Co.). The membrane was blocked overnight at 
room temperature using a blocking solution of 1X Saline-Sodium Citrate (SSC), 1% 
Bovine Serum Albumin (BSA) (Fisher Scientific, Pittsburgh, PA, USA), and 1% Sodium 
Dodecyl Sulfate (SDS) (Sigma Chemical Co.). A one hour incubation at room 
temperature was then performed using 20pmol biotinylated primary probe directed to 
the TCRBC region (Integrated DNA Technologies, Inc.) per mL blocking buffer followed 
by three five minute washings with a wash buffer of 1X SSC and 1% SDS (Sigma 
Chemical Co.). A streptavidin-HRP conjugate (Amersham Biosciences, Piscataway, NJ, 
USA) was added at a 1:5000 dilution in blocking buffer for 1 hour at room temperature. 
Three final five-minute washes were performed using the wash buffer. The membrane 
was developed using ECL™ detection reagents (Amersham Biosciences) according to 
the manufacturer’s instructions. The membrane was then exposed to Biomax™ MR film 
(Eastman Kodak Company, Rochester, NY, USA). The film was developed using a 100 





Primer Sequence Panel 
 
The final TCRBV primer panel consists of fewer than 30 primers and one 
TaqMan® probe. The amplification of the various alleles and subfamily members for a 
given TCRBV family is diagrammed in Table I. As previously mentioned, each TCRBV 
family can have multiple subfamily members, some with additional alleles. As described 
by Arden, et al. 3, we have adhered to the accepted classification and nomenclature for 
these families and their subfamily and allele members.  
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Listed on the far left columns of Table 1 are the names of the primers and their 
respective TCRBV families, whose subfamily and allele members are listed in the 
adjacent column. A single primer was used for the amplification of a given TCRBV with 
the following exceptions: two primers were needed to amplify all BV6 (B6JLB2 and 
B6JLB3), BV12 (B12.1JLB and B12.2.3JLB), and BV13 (B13.1eJLB2 and B13.5JLB2) 
members. There is no primer to amplify BV10 or BV19 as these families only contain 
nonfunctional orphan or pseudogenes 3.  
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primer TCR TCR TCR GenBank
name(s) family subfamily sequence accession 
 
#
B1H B variable 1 BV1S1A1 PL5.2 M13836
BV1S1A2 308C M27904





B3H B variable 3 BV3S1 PL4.4 M13843
B4H B variable 4 BV4S1A1 PL2.14 M13846
BV4S1A2 HBP48 X04926
BV4S1A3 PL5.7 M13847





































B9H B variable 9 BV9S1A1 HT307 X57614
BV9S1A2 VB9.n L06889
B11H B variable 11 BV11S1A1 PL3.12 M13861
BV11S1A2 1.3 X74845















B14JLB2 B variable 14 BV14S1 PL8.1 M13865
B15H B variable 15 BV15S1 ph32 M14269
B16H B variable 16 BV16S1A1 HT370 X57723
B17Blum B variable 17 BV17S1A1 HBVT02 M27388
BV17S1A2 S30.10 M97725
BV17S1A3 BV17S1 L19936
B18JLB B variable 18 BV18S1 HBVT56 M27389
B20JLB2 B variable 20 BV20S1A1 WBDM30A D13086
BV20S1A3 HUT102beta M13554
B21JLB B variable 21 BV21S1 B17ct7 D16584
BV21S2A1 IGRb02 X58797
BV21S2A2 BV21.2 M33234
BV21S2A3 V beta 21 M62377
BV21S3A1 BV21.3 M33235
BV21S3A2 IGRb01 X58796
B22H B variable 22 BV22S1A1 V beta 23 M62379
BV22S1A2 IGRb03 X58798
B23JLB2 B variable 23 BV23S1A1 V beta 22 M62378
BV23S1A2 IGRb04 X58799
B24H B variable 24 BV24S1A1 V beta 24 M62376
BV24S1A2 IGRb05 X58800
BV24S1A3 H130.1 U03115
B25JLB B variable 25 BV25S1A1 HVB30.A L26231
BV25S1A3 HsVB25 L26054
CBJLB B constant BC1 JM K02885
BC2 L34740
TCRCB probe B constant BC1 JM K02885
BC2 L34740
 
Table 1: TCRBV primer panel organization. 
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The third column from the left in Table I, entitled TCR subfamily, contains all of 
the subfamily (S) and alleles (A) for a given TCR family, per the previously described 
nomenclature system 3. The final two columns of Table I, titled TCR sequence and 
GenBank accession #, provide the reference sequences used in the development of our 
primer sequences. When available, we have provided both the sequence clone name 
as well as its listing in the GenBank database. Primer sequences are proprietary and 
are available for licensing through the Institute for Scientific Research, Inc. (Fairmont, 
WV)  
 
Peripheral Blood Composition Analysis 
 
The cellular composition of the peripheral blood from three healthy human 
donors is presented in Table II. Cellular composition is as expected for healthy donors. 
It was found that lymphocyte samples range from 30%-55% CD4+ T cells, 22%-44% 
CD8+ T cells, and 4%-11% CD19+ B cells. 
 
CD19+
WBC neutrophils eosinophils basophils monocytes lymphocytes CD4+
sample (103/uL) CD8+
4.11%
A 3.73 57.00% 1.73% 0.69% 8.98% 31.60% 54.75%
21.65%
6.32%
B 3.38 44.20% 8.08% 0.58% 6.51% 40.60% 29.62%
43.62%
10.61%





Table 2: Peripheral blood composition of donor samples.  
All values are expressed as percent, except white blood cell (WBC) count, which is expressed as 
thousand cells/microliter. Lymphocyte counts were further differentiated into percent CD19+, CD4+ 





iCycler™ fluorescence signal corresponds to Southern Blot signal 
 
Figure 1 depicts the fluorescence readings obtained on the iCycler™ using the 
B1H/CBJLB primer set with the TCRCB TaqMan® probe. Fluorescence readings (RFU) 
are reported here as the Ct value, or the cycle at which fluorescence readings exceeded 
background fluorescence levels. Those samples with greater initial levels of target  
template have fluorescence 
levels that more quickly surpass 
these background fluorescence 
levels, or a lower Ct value, compared 
to samples with less initial copies of 
target template. The plus and minus 
template samples are indicated in 
Figure 1. The plus template sample 
has a Ct value of 12 while the no 
template sample has an expected 
Ct value >34. Plus and minus 
template samples were completed for all TCR variable family primers to ensure the 
absence of autofluorescence in the no template samples. No significant 
autofluorescence levels were detected with the TCRBC TaqMan® probe and any of the 
TCRBV primers.  
Figure 1: iCycler fluorescence readings during 
amplification of TCRBV1. 
In order to confirm the fluorescence readings obtained by the iCycler™, Southern 
Blot analysis was performed on randomly chosen TCRBV PCR products. As exampled 
by the B1H/CBJLB amplification product shown as the inset in Figure 1, the iCycler’s™ 
fluorescence readings are independently confirmed by Southern Blot analysis. Again, 





Amplification Efficiency Determination 
 
cDNA was diluted into 10 fold serial 
dilutions and subjected to PCR amplification 
to determine the degree of amplification 
efficiency. Figure 2 depicts the fluorescence 
levels seen with the amplification reaction 
using the primer B6JLB2. The reaction using 
this primer was ~93% efficient, results which 
are typical for the other analyzed primer 
sets. This amplification efficiency determination indicates that the PCR detection system 
is sensitive in response to the amount of target template initially placed into the reaction 
(refer to appendix for amplification efficiency calculation equation). 
Figure 2: Amplification efficiency analysis. 
 
 
TCRV family gene expression as determined by real-time PCR 
 
Figure 3 depicts the TCRBV expression profiles from three human peripheral blood 
samples. Each data point is the mean of triplicate reactions with the standard error of 
the mean indicated. One way Analysis of Variance with Tukey’s Post Hoc test was 
performed for statistical analysis. Symbols indicate significant differences between the 
three samples for a given primer. $$(P<0.001), #(P<0.01), and *(P<0.05). Significant 
differences in expression levels were seen between samples A, B, and C for TCRBV8, 
12, 15, 16, 17, 18, 20, 23, and 25. Both TCRBV mRNA and protein expression levels 
(determined using the IOTest® Beta Mark TCR VB Repertoire Kit (Beckman Coulter)) 





Figure 3: Relative TCRBV mRNA expression levels of three human 
peripheral blood samples based on Ct values  
Figure 3: Relative TCRBV mRNA expression levels of three human peripheral blood samples based on Ct 
values 
(samples A, B, and C). $$ (P<0.001), # (P<0.01), * (P<0.05). 
 Note: A Ct difference of ~3.5 cycles was required to achieve 95% confidence, or p<0.05 
 
Figure 4 depicts the relative TCRBV1 expression profile, as determined by Ct 
values, of a hematopoietic stem cell transplant patient prior to and following transplant. 
The patient was a 54 year-old male being treated for chronic lymphocytic leukemia and 
received peripheral blood hematopoietic stem cells from a matched related donor. The 
patient had a staphylococcus infection, as well as graft-versus-host disease and 
cytomegalovirus complications, immediately following transplant. These complications 
resolved but the patient expired at week 14 post- transplant from graft-versus-host 
disease complications. Significant changes in TCRBV1 expression were observed over 
time between weeks –1 and 3, weeks 3 and 4, weeks 7 and 8, and weeks 8 and 9. 
Figure 4:TCRBV1 expression level changes in a hematopoietic stem cell transplant recipient before and 
after transplant. 
 
Each data point is the mean of triplicate reactions with the standard error of the mean indicated. One 
way Analysis of Variance with Bonferroni’s Multiple Comparison test was performed for statistical 








Through the employment of primer panels previously developed 4-49, many 
investigators have examined the usage of the human TCR beta variable genes under 
various biological conditions. Many of these reports, however, fall short of the desired 
comprehensiveness to detect all TCRBV members. For example, due to the more 
recent identification and classification of TCRBV families 21, 22, 23, 24, and 25, many 
previous reports do not include analysis of some or all of these additional five families 4-
17,20-30,32-39,41-43,45,46. Additionally many also would not amplify all subfamily and allele 
members within a given TCRBV family. For example, based on sequence homology 
analysis the panel proposed by Blumberg, et al., 7 will not amplify the subfamily member 
BV8.3. 
Others have tried different approaches to the amplification of all TCRBV 
subfamily and allele members. For example, Lynas, et al., 28 describe the use of single 
primers to detect BV2/BV4 and BV18/BV8.3. Tsuruta, et al., 44 have five separate 
primers in their panel to amplify all members of the TCRBV5 family while we have been 
able to identify a single primer sequence that we predict will amplify all 5 subfamilies 
(including all 11 possible alleles). Therefore, a primer panel that will amplify all possible 
alleles for the TCRBV families using as few primers as possible is a noteworthy 
improvement in the area of T cell receptor gene expression analysis, as sample 
availability is often a limiting factor.  
While most of the previously cited primer panels we reviewed relied on 
conventional PCR, followed by gel analysis and Southern Blotting or the inclusion of 
labeled primers or nucleotides for sequence analysis there is at least one report of the 
use of TCRBV primers in a SYBR green reaction 42. While the paper by Sebille et al., 
yields to the same primer sequence concerns as many of the others, as it traces its 
primer sequence roots back to the primers described by Genevee et al., 15 and Gorski et 
al., 17, this does move the field of TCRBV gene expression analysis into the real-time 
PCR arena. We have experimented with SYBR green reactions previously but prefer 
the ease of analysis and additional sequence specificity offered by a TaqMan® probe. 
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While our study focuses on the use of peripheral blood samples, there is nothing 
intrinsic about our method that prevents using cells from other sources, for example cell 
cultures, tissue samples, or synovial fluid. We have previously used silica membrane-
based extraction kits, such as GenElute™ Mammalian Total RNA Kit (Sigma Chemical 
Co.), Rneasy® kit (Qiagen) and PAXgene™ Blood RNA kit (PreAnalytiX, Switzerland). 
However, we chose to isolate RNA from our samples using phenol-chloroform 
extraction, due to our success with improved yields compared to the silica membrane-
based technologies. While we chose to use the BioRad iCycler™ due to its availability 
at our facilities, its larger sample capacity, and the permitted usage of conventional PCR 
tubes, we have previously used the Roche Lightcycler®, demonstrating the flexibility of 
platform usage but not validity that the primers provide equivalent results across all 
platforms. 
Consistent with previous reports 51-54, differences in TCRBV expression levels do 
exist between individuals and the level of those differences can change with time and 
health of the individual.  Our technology has not only been demonstrated functional by 
the usage of sequence specific probes in real time PCR but has also been verified by 
Southern Blot analysis and flow cytometry utilizing available TCRBV antibodies, with the 
latter supporting the notion that the increased expression levels we observed with the 
PCR system were due to the increased number of cells expressing such receptors as 
opposed to only an increase in the amount of message in a given cell.  
In terms of amplification efficiency, if a PCR reaction is 100% efficient, there will 
theoretically be a decrease in the Ct value by one each time the template amount is 
doubled (Roche Molecular Biochemicals, Technical Note No. LC 11/2000). Therefore, 
for a 10-fold dilution, a difference of 3.25 cycles should be observed between each 10-
fold dilution. Our methodology is not only comprehensive but it is also efficient with a 
typical amplification efficiency of ≥ 90%. 
In conclusion, we have presented here a significant improvement to existing 
technologies that enable one to detect all of the families, subfamilies, and alleles of the 
TCRBV regions classified by Arden et al., 3 using efficient, sequence specific real-time 
PCR methodology. The user benefits from automated and integrated amplification, 
detection, and analysis in a gel free environment with the choice of using various PCR 
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platforms, sample sources, and sample processing methods. Additionally, this PCR-
based method is approximately 25-fold less expensive than comparable flow cytometry 
based methods. This technology can be applied to any area of study examining T cell 
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THE PREVIOUS CHAPTER DESCRIBED THE DEVELOPMENT OF IMPROVED 
TECHNOLOGY CAPABLE OF ACCURATELY AND EFFICIENTLY DETECTING 
EXPRESSION OF ALL OF THE HUMAN TCRBV GENES.  
 
THERE ARE MANY POTENTIAL APPLICATIONS OF SUCH TECHNOLOGY. 
 
FOR MY PURPOSES, HOWEVER, I UTILIZED THE TECHNOLOGY TO DETERMINE 
WHAT SPECIFIC T CELLS ARE ASSOCIATED WITH THE FOLLOWING SPECIFIC 




1) GRAFT-VERSUS-HOST DISEASE 
2) CYTOMEGALOVIRUS REACTIVATION 
3) IMMUNOSUPPRESSIVE THERAPIES (CYCLOSPORIN A AND TACROLIMUS) 
















SIMILARITY IN REPERTOIRE OF T CELLS ASSOCIATED WITH 
OCCURRENCES OF CMV REACTIVATION AND GVHD POST HUMAN 






Cytomegalovirus (CMV), after initial infection, typically remains in a latent state 
and reactivates during periods of immune suppression, such as after allogeneic 
hematopoietic stem cell (HSC) transplant. Prior studies have indicated a restricted 
usage of specific TCRBV families directed against CMV antigens in otherwise healthy 
individuals. We monitored, on a weekly basis, the usage of the T cell receptor beta 
variable (TCRBV) repertoire in the peripheral blood of five HSC transplant recipients 
using real-time RT-PCR and found that several TCRBV families (TCRBV 1-6, 11, 12.1, 
13 (excluding 13.5), 15, 16, 20, 25) were significantly associated with CMV reactivation. 
In addition, significant overlap exists in these families and those found to be associated 
with graft-versus-host disease (GVHD), a common T cell mediated post transplant 
complication. Our results may help to explain the common clinical association of CMV 





Cytomegalovirus (CMV) is a human herpes virus that infects greater than 60% of 
the world’s adult population1. While this virus typically presents itself as a latent 
infection, it commonly reactivates during immuno-suppressed states, such as after 
allogeneic hematopoietic stem cell transplant (HSCT) 2. Prior studies have indicated a 
restricted usage of specific T cell receptor beta variable (TCRBV) families directed 
against CMV antigens in otherwise healthy individuals 3-6. We here examine the 
expression of specific TCRBV families associated with CMV reactivation following 
allogeneic hematopoietic stem cell (HSC) transplantation. In addition, we determined 
that overlap exists in the TCRBV families associated with CMV reactivation and graft-
versus-host disease (GVHD), supporting previous reports of the clinical association of 
GVHD and CMV reactivation 7-9. GVHD is a common post transplant complication 
where the donor-derived T cells attack and destroy the recipient’s tissue based upon 
allogeneic disparities between the T cell receptor (TCR) and peptide:major 
histocompatibility complex (p:MHC) 10. In our study peripheral blood samples were 
collected weekly from allogeneic HSC recipients through day 100 post-transplant. Donor 
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and recipient peripheral blood samples were also collected prior to pre-transplant 
conditioning therapies in order to serve as baseline reference samples. Despite the 
complexities of the post transplant environment, we found that specific subsets of T 
cells were significantly associated with CMV reactivation and that many of these same 
TCRBV families were also associated with the development of GVHD in the patient 








Study subjects were patients undergoing allogeneic transplant treatment at West 
Virginia University’s Blood and Marrow Transplant and Hematological Malignancy 
Program, Morgantown, West Virginia (Table 1). Informed consent was obtained from 
participants after the nature and possible consequences of the study had been fully 
explained according to West Virginia University’s Institutional Review Board guidelines. 
Prior to peripheral blood stem cell (PBSC) infusion, study recipients underwent 
myeloblative conditioning regimens consisting of either Thiotepa (500 mg/m2 q12h x 2 
doses), Campath-1H (20mg x 2 doses), and total body irradiation (TBI) (200 cGy x 5 
fractions) or Busulfan (1mg/kg p.o. q6h x 16 doses) and Cytoxan (60 mg/kg/d x 2 
doses). A 20 mL peripheral blood sample was collected weekly, via venipuncture from 
hematopoietic stem cell transplant patients, into an acid citrate dextrose 
VACUTAINER™ blood collection tube (Becton Dickinson, Franklin Lakes, NJ, USA). 
Buffy coat layers were isolated via centrifugation at 3300 rcf for 10 minutes. 
Contaminating red blood cells were removed by hypotonic lysis.  
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recipient sex age disease donor pretreatment CMV status post tranplant 
regimen recipient/donor complications





2 M 54 CLL MRD TT/TBI/Campath pos/neg GVHD grades II and IV
CMV reactivation
staphylococcus infection
3 M 51 NHL MRD TT/TBI/Campath pos/neg GVHD grade II
CMV reactivation
staphylococcus infection









Table 1: Patient demographics 
 
All patients received peripheral blood hematopoietic stem cell transplants from an HLA-matched related 
donor (MRD) with the exception of recipient 5, who received stem cells from an HLA-matched unrelated 
donor (MUD). HLA matching was performed serologically for all MRD but was determined using 
molecular typing for MUD. Cytomegalovirus (CMV) status was determined in both recipient and donor 
prior to transplant by evaluating CMV IgG and IgM serum levels. CMV reactivation was monitored weekly 
by antigenemia testing for recipients at risk for CMV reactivation (donor and/or recipient with prior history 
of CMV exposure). Complications experienced in the recipient post transplant, as determined by standard 
clinical evaluation, are indicated on the far right side of the table. All patients were living at the conclusion 
of our study. Abbreviations: M, male; F, female; AML, acute myelogenous leukemia; CLL, chronic 
lymphocytic leukemia; NHL, non-Hodgkin lymphoma; CML, chronic myelogenous leukemia; TT, Thiotepa; 




All donors were serologically HLA matched to the recipient at a minimum of HLA-
A, B, and DR loci. The patient undergoing an unrelated donor transplants was also 
molecularly matched at the allele level. PBSC donors were mobilized with filgrastim (G-
CSF) at 10ug/kg/day for 5 days with stem cell collection occurring on day 5. The 
number of PBSC collected was 3-5 x 106 HSC/kg of recipient body weight.  
 
 
GVHD Prophylaxis and Supportive Care 
 
Cyclosporin A (CSA) or tacrolimus (FK506) treatment started one day before 
transplant (d-1) as part of standard graft-versus-host disease prophylaxis and continued 
throughout the study period. The patients also received pulse methotrexate as part of 
GVHD prophylaxis. Patients were monitored bi-weekly for CSA and FK506 serum 
concentrations, with dosages adjusted as necessary to be within the preferred protocol 
serum concentrations of 200+/-20 ng/mL for CSA and 7-12 ng/mL for FK506. Additional 
supportive care, including anti-fungal, anti-viral, and anti-PCP prophylaxis were 
provided according to standard operating policies. CMV reactivation was monitored 





Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent 
according to the manufacturer’s directions (Ambion, Austin, TX, USA). RNA was 
dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen 
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA 
according to the manufacturer’s recommendations using DNA-free™ (Ambion, Austin, 
TX, USA). RNA purity and concentration was determined by standard 260nm:280nm 
spectrophotometric analysis using a Genesis 10UV Spectronic Unicam (Spectronic 






One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit 
(Qiagen, Valencia, CA, USA). Recommended reaction mixtures were scaled down to a 
total reaction volume of 20 µL using 0.04 µg RNA with the following primer and probe 
concentrations: 0.4 µM TCRBV primer (Biosource International, Camarillo, CA, USA), 
0.4 µM TCRBC primer (Biosource International, Camarillo, CA, USA), and 0.2 µM 
TCRBC TaqMan® probe, 5’ 6-FAM, 3’ BHQ™-1 (Integrated DNA Technologies, Inc., 
Coralville, IA, USA). 18SrRNA control reactions were performed in parallel using 0.4 µM 
each of sense and anti-sense primers (Biosource International, Camarillo, CA, USA) 
and 0.2 µM 18SrRNA TaqMan® probe, 5’ 6-FAM, 3’ BHQ™-1 (Integrated DNA 
Technologies, Inc., Coralville, IA, USA). Primer and probe sequences were previously 
described (Brewer and Ericson, J. of Immunol. Methods, in press). An iCycler™ 
(BioRad Laboratories, Hercules, CA, USA) was used for the RT and amplification 
cycles. RT was performed at 50oC for 60 minutes, max ramp speed, followed by an 
initial Taq activation step of 15 minutes at 95oC, max ramp speed. A TouchDown PCR 
approach 11 was used with the following cycling conditions: denaturation for 15 seconds 
at 95oC, max ramp speed, annealing for 30 seconds starting at 70oC decreasing by 2oC 
for 10 repeats, max ramp speed, and extension for 40 seconds at 72oC, min ramp 
speed. After this TouchDown of the annealing temperature, 50 cycles were performed 
as follows with the optical data collection occurring at the extension step: 15 seconds at 
95oC (max ramp speed), 30 seconds at 52oC (max ramp speed), and 40 seconds at 





One-way analysis of variance with Bonferroni’s Multiple Comparison Test was 








Increased expression of specific TCRBV families is associated with reactivation 
of cytomegalovirus post peripheral blood hematopoietic stem cell transplant. 
 
Using serial time points, we analyzed the alterations in TCRBV expression over 
time to determine which TCRBV families were associated with CMV reactivation 
compared to periods without CMV reactivation. All patients in our study were 
determined to be 100% donor engrafted at day 30 post-transplant, with the exception of 
recipient 5, whose chimerism analysis was not performed until day 100 post transplant, 
at which point chimerism was also determined to be 100% donor in origin. We found an 
increase in the expression of TCRBV families 1-6, 11, 12.1, 13 (excluding 13.5), 15, 16, 
20, and 25 with CMV reactivation compared to sampling periods in which CMV 
antigenemia was not detected (Table 2).  
 
Increased expression of specific TCRBV families is associated with Graft-versus-
Host Disease post peripheral blood hematopoietic stem cell transplant and has 
significant similarity to those families linked to CMV reactivation. 
 
In addition to investigating the increased expression of specific TCRBV families 
in the setting of CMV reactivation, we also examined the expression profiles of TCRBV 
families associated with GVHD post HSC transplant. By weekly monitoring of the T cell 
repertoire, in addition to baseline sampling, we were able to circumvent some of the 
concerns associated with previous GVHD reports, such as the lack of baseline samples 
and serial time point analyses 12-17. All five of our patients developed acute GVHD post 
HSCT, primarily grades I-II (Table 1). When we examined the TCRBV expression profile 
during periods when patients had GVHD and compared this to periods without GVHD, 
we found significant increases in the expression of TCRBV 1-6, 12.1, 13 (excluding 
13.5), and 16, associated with GVHD grades I-II, with an additional increase in TCRBV 
18 seen in a patient with GVHD grade IV (Table 2).  
 
70 
TCRBV increases associated with TCRBV increases associated with















Table 2: Increased expression of specific families of TCRBV is associated with cytomegalovirus (CMV) 
reactivation and Graft-versus-Host Disease (GVHD) post peripheral blood stem cell transplant. 
Specific TCRBV families were significantly increased (p<0.05) with the occurrence of CMV reactivation, 
compared to periods in which CMV antigenemia was not detected and also with the occurrence of GVHD 
grades I and II, compared to periods without GVHD complications. *In a patient with grade IV GVHD an 






A number of studies have examined the role of specific T cells in the immune 
response to CMV antigens. While a previous study looking at the TCRBV expression 
during CMV reactivation in kidney and liver transplants found no preference for TCRBV 
usage 18, we found great similarity in our results and those examining the TCRBV 
expression of CMV reactive T cells found in otherwise healthy individuals 3-6. For 
example, studies using CMV reactive T cell from healthy donors expressed TCRBV 
families 2 and 20 6, TCRBV families 3, 6.7, 13.1, and 20 5, and TCRBV families 1, 2, 
5.1, 12, 13.1, and 16 3. Many of these previous studies utilized tetramer technology to 
remove CMV reactive T cells, which were then analyzed for TCRBV expression via 
antibody staining and flow cytometry. The greatest limitation of previously described 
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studies is that antibodies were not available to all of the TCRBV families, such as 
TCRBV 4, 11, 13, 15, and sometimes 25. We suspect that the reason we detected the 
expression of additional TCRBV families with CMV reactivation compared to these 
previous studies was that we used a primer panel that could detect all of the TCRBV 
families and their alleles.  
Similarly a number of reports have described the association of specific TCRBV 
families with GVHD, with some of these studies not only examining peripheral blood 
samples but also GVHD tissue lesions 12-17,19-25. Many of these studies, however, 
contained very limited numbers of sampling points; for example some studies primarily 
evaluated samples upon the diagnosis of GVHD and others did not contain baseline 
sampling 12-17. In this aspect, our study significantly adds to the investigation of immune 
response after hematopoietic stem cell (HSC) transplantation by providing serial time 
point analyses using a comprehensive primer panel, which can detect all TCRBV 
families and alleles.  
Several reports have detailed the clinical association of GVHD and CMV 
reactivation 7-9. Larsson et al., observed a decreased risk for the development of GVHD 
when patients were preemptively treated with anti-viral therapy 7,8 while Vassallo et al., 
observed an association between skin GVHD and the presence of CMV antigens in the 
patient’s peripheral blood 9. A recently published study noted cross reactivity of an HLA-
DR7 restricted CMV-specific T cell for an HLA-DR4 allo-antigen 7. This could possibly 
account for the overlap we saw in TCRBV families associated with both GVHD and 
CMV reactivation.  
In conclusion, the developing immune system found in hematopoietic stem cell 
transplant patients responds to CMV antigen exposure with the alteration of the TCRBV 
profile with great similarity to that described in prior non-transplant related reports. 
Additionally, great similarities exist in the alterations of the TCRBV profile associated 
with CMV reactivation and the occurrence of GVHD, supporting prior reports of such a 
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ENGRAFTMENT OF T CELL RECEPTOR (TCR) REPERTOIRE IN 
MYELOABLATED ALLOGENEIC HEMATOPOIETIC STEM CELL 




Hematopoietic stem cell (HSC) transplantation is used to rescue the immune 
system in patients who have received myeloblative regimens targeted at eradication of 
various hematological malignancies. In allogeneic HSC transplantation, stem cells from 
a healthy donor are infused into the recipient with the intent of reconstituting the 
recipient’s immune system. Using the most comprehensive set of TCRBV primers 
available, we determined through real time RT-PCR that the reconstitution of the 
recipient’s T cell repertoire post- hematopoietic stem cell transplant was of a higher 
correlation to that found in the donor compared to that found in the recipient prior to 
transplant. Our results argue that, despite the influence of the recipient’s environment, 
the donor stem cells mature in the recipient’s body with a TCRBV repertoire reminiscent 




The major goal of allogeneic hematopoietic stem cell transplantation is to achieve 
complete engraftment of healthy donor hematopoietic stem cells and subsequent 
immune reconstitution within the new environment of the recipient. T cells are a critical 
component of the recipient’s defense system against invading pathogens and the 
reactivation of latent infections through the recognition of antigen through the T cell 
receptor (TCR). While T cells play a critical role in the immune system’s defenses, it is 
not known whether the maturing T cells found in the recipient display a T cell receptor 
beta variable (TCRBV) repertoire more like that in the donor or if they exhibit a 
repertoire more reminiscent of that found in the recipient prior to transplant. In this 
study, we used real-time RT-PCR and a comprehensive panel of primers, developed in 
response to the reclassification of the TCR genes 1, to monitor the profile of the 
engrafting TCRBV regions. In the first 100 days after transplant, despite the influence of 
the recipient’s HSC environment on the development of the immature cells 2-4, the T cell 
repertoire appears to develop with a phenotype more reminiscent of that found in the 
donor as opposed to that found in the recipient prior to transplant. 
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Study subjects (n=4) were patients undergoing transplant treatment at West 
Virginia University’s Blood and Marrow Transplant and Hematological Malignancy 
Program, Morgantown, West Virginia. Informed consent was obtained from participants 
after the nature and possible consequences of the study had been fully explained 
according to West Virginia University’s Institutional Review Board guidelines. All study 
patients received hematopoietic stem cells collected from the peripheral blood of 
mobilized donors who had been primed with G-CSF. The donors were serologically HLA 
matched to the recipient at a minimum of HLA-A, B, and DR loci. Prior to peripheral 
blood stem cell (PBSC) infusion, study recipients underwent myeloblative conditioning 
regimens consisting of either Thiotepa (500 mg/m2 q12h x 2 doses), Campath-1H 
(20mg x 2 doses), and total body irradiation (TBI) (1000 cGy total dose: given in 200cGy 
fractions) or Busulfan (1mg/kg p.o. q6h x 16 doses) and Cytoxan (60 mg/kg/d x 2 
doses) (Table 1). Full supportive care, including GVHD prophylaxis, anti-fungal, anti-
viral, and anti-PCP prophylaxis, empiric anti-microbial therapy for neutropenic febrile 
episodes, and transfusions were provided per standard operating policies. Peripheral 
blood, ~20 mL, was collected weekly, via venipuncture from hematopoietic stem cell 
transplant patients, into an acid citrate dextrose VACUTAINER™ blood collection tube 
(Becton Dickinson, Franklin Lakes, NJ, USA). Buffy coat layers were isolated via 
centrifugation at 3300 rcf for 10 minutes. Contaminating red blood cells were removed 
by hypotonic lysis. 
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recipient sex age disease donor pretreatment immunosuppressive CMV status
regimen therapy recipient/donor
1 M 54 AML MRD TT/TBI/Campath CSA neg/neg
2 M 54 CLL MRD TT/TBI/Campath CSA pos/neg
except for w+12 
when switched to FK506 
to treat GVHD IV
3 M 51 NHL MRD TT/TBI/Campath CSA pos/neg
4 F 41 CML MUD Bu/Cy2 CSA pos/pos
 
Table 1: Patient demographics 
 
All patients received peripheral blood hematopoietic stem cell transplants from an HLA-matched related 
donor (MRD). HLA matching was performed serologically. Cytomegalovirus (CMV) status was determined 
in both recipient and donor prior to transplant by evaluating CMV IgG and IgM serum levels. Complications 
experienced in the recipient post transplant, as determined by standard clinical evaluation, are indicated on 
the far right side of the table. All patients were living at the conclusion of our study. Abbreviations: M, male; 
F, female; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin 
lymphoma; CML, chronic myelogenous leukemia; TT, Thiotepa; TBI, total body irradiation; Bu, Busulfan; 
Cy2, Cytoxan; GVHD, graft-versus-host disease. 
RNA Isolation 
 
Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent 
as previously described (Brewer and Ericson, J. of Immunol. Methods, in press). RNA 
was dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen 
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA 
according to the manufacturer’s recommendations using DNA-free™ (Ambion, Austin, 
TX, USA). RNA purity and concentration was determined by standard 260nm:280nm 
spectrophotometric analysis using a Genesis 10UV Spectronic Unicam (Spectronic 






One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit 
(Qiagen, Valencia, CA, USA) with sequence specific detection as previously described 




Spearman rank correlation coefficient analysis was used to determine the 
correlation of the TCRBV engraftment phenotypes.  
 
 
RESULTS AND DISCUSSION 
 
The TCRBV repertoire engrafts with a phenotype similar to that present in the 
donor. 
 
By analyzing the expression of all of the TCRBV families in the donor and 
recipient pre-transplant followed by weekly analysis of these families in the recipient 
post transplant, we could monitor the TCRBV phenotype of the recipient’s engrafted 
cells during the early reconstitution period (Table 2). While neutrophil engraftment 
begins one to two weeks after transplant, complete restoration of the CD3+ population 
typically requires many months post-transplant 5. We compared correlation parameters 
at weekly intervals and here report the correlation seen at baseline and at day 100. The 
day 100 TCRBV expression patterns obtained from patients 1, 2, and 3 showed a 
stronger correlation to the baseline donor TCRBV expression profile compared to the 
recipient’s baseline TCRBV repertoires (sample 1: -0.193 vs. 0.68, sample 2: 0.330 vs. 
0.510, sample 3: 0.329 vs. 0.664). At the conclusion of this study, there was a 
decreased correlation of recipient samples to their own pre-transplant TCRBV profile 
when compared to the donor’s baseline TCRBV expression profile (sample 1: -0.219 vs. 
0.68, sample 2: 0.289 vs. 0.510, sample 3: 0.537 vs. 0.664). These results were 
compared to the correlation of the TCRBV repertoire found in healthy peripheral blood 




sample correlation to self correlation to donor correlation to self correlation to donor
t =0 (baseline) t =0 (baseline) t =d+100 t =d+100
recipient 1 1 -0.192820513 -0.218803419 0.68
recipient 2 1 0.33025641 0.289230769 0.51042735
recipient 3 1 0.329230769 0.536752137 0.663931624
recipient 4 1 0.517264957 0.361367521 0.246495726
healthy volunteer correlation to self correlation to self
donors t =0 (baseline) t =+2 weeks
donor 1 1 0.748462
donor 2 1 0.756154
donor 3 1 0.789231
donor 4 1 0.742692
 
Table 2: The TCRBV repertoire engrafts with a phenotype similar to that present in the donor. 
Spearman rank correlation coefficients were determined for the TCRBV repertoire expression 
in both recipient and donor prior to transplant (baseline) and at the conclusion of the study 
(day +100). A correlation coefficient of one represents a perfect correlation. All recipients, 
with the exception of recipient 4, had a greater correlation to the donor than to themselves at 
day +100. This is compared in the context of the TCRBV repertoire observed in healthy 
individuals over a two-week period.  
 
 
With a single exception, recipient 4, we observed the engraftment of a T cell  
receptor phenotype with greater correlation to baseline profiles found in the donors, as 
opposed to those found in the recipients, prior to transplant. Recipient number 4 was 
the only patient in our study who received a different pre-conditioning regimen, Cytoxan 
and Busulfan, compared to the TT/TBI/Campath-1H regimen. One possible explanation 
for this difference is the highly T-cell suppressive effect observed in patients who 
receive a preparative regimen containing Campath-1H (anti-CD52), an agents whose 







All patients were determined to be 100% donor engrafted at day 30 post-
transplant, with the exception of recipient 4, whose chimerism analysis was not 
performed until day 100 post transplant, at which point chimerism was also determined 
to be 100% donor in origin. While these results are preliminary, they suggest that the 
developing TCRBV repertoire in the recipient is more closely reflecting that found in the 
donor as opposed to that found in the recipient prior to transplant. It is unlikely that 
these results are attributable to mature donor T cells found within the graft as recipients 
received Campath therapy (anti-CD52), which targets T cells for antibody dependent 
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CYCLOSPORINE A (CSA) AND TACROLIMUS (FK506) 






Cyclosporin A (CSA) and tacrolimus (FK506) are two common 
immunosuppressive agents used post blood and marrow transplantation. They exert 
their effects through the inhibition of calcineurin activity and subsequent inhibition of IL-2 
production. IL-2 is a cytokine needed for proliferation of activated T cells, an immune 
cell commonly responsible for post transplant complications such as graft rejection and 
graft-versus-host disease. Despite similarity in their mode of action, we observed 
polarized effects of CSA and FK506 on the human T cell repertoire, as monitored 
through the expression of the T cell receptor beta variable (TCRBV) regions. To 
determine the possible mechanism for this difference, in vitro experiments using the 
Jurkat human T-cell line were performed. The effects of CSA and FK506 on cell 
viability, cell proliferation, IL-2 production, and calcineurin inhibition were determined 
and no significant differences between the two agents were observed. The data suggest 
that a secondary mechanism of action exists for the different TCRBV repertoire induced 




Immunosuppressive agents are widely used in the treatment of various medical 
conditions, in particular for allogeneic blood and marrow transplantation (BMT). Post 
transplant recipients are at a significant risk of rejecting their graft or developing a 
condition known as graft-versus-host disease (GVHD). T lymphocytes are known to be 
the primary immune mediators of such reactions 1,1-5. Cyclosporin A (CSA) and 
tacrolimus (FK506) are two commonly employed agents used to prevent allograft 
rejection and to decrease the risk of developing GVHD in the BMT setting 6. 
Figure 1: Abbreviated schematic of the signaling pathway activated by engagement of the T cell receptor 
(TCR) and its inhibition by CSA and FK506. 
Abbreviations: p:MHC, peptide:major histocompatibility complex; TCR, T cell receptor; ITAMS, 
immunoreceptor tyrosine-based activation motifs; PLC, phospholipase C; PIP-2, phosphatidylinositol 
biphosphate; IP3, inositol triphosphate; DAG, diacylglycerol; Ca2+, calcium; CaM, calmodulin; PKC, 
protein kinase C; CSA, cyclosporin A; FKBP, FK-binding protein; NFAT, nuclear factor of activated T 






The overall effect of CSA and FK506 is to impair the production of interleukin 2 
(IL-2) by T lymphocytes. This is accomplished through the binding of CSA and FK506 to 
cyclophilin 7,8 and FK506-binding proteins 9-12, respectively. This binding causes the 
subsequent inhibition of the protein  calcineurin, a protein critical to the production of IL-
2 (Figure 1) 13-16. IL-2 is produced primarily by activated T cells and is required for T cell 
proliferation 17. Since extensive similarities  (including mechanism of action and agent 
entry into cells) exist between CSA and its derivative, FK506 18, suppression of the T 
lymphocyte response is expected to be comprehensive and similar between the two 
agents. However, we observed polarized effects of CSA and FK506 on the T cell 
repertoire, as monitored through T cell receptor beta variable region (TCRBV) 
expression patterns. FK506 suppressed the expression of the majority of TCRBV 
families while an increased expression in specific TCRBV families was observed with 
CSA. Cell viability, proliferation, IL-2 production, and calcineurin activity in response to 
CSA and FK506 treatments were measured in vitro using the Jurkat human T-cell line. 
In addition to their extensive usage as an in vitro human T cell model, Jurkat cells were 
selected based upon their expression of TCRBV8 19, a TCR that showed varied 
responses to CSA and FK506 in our experiments. The experiments were designed to 
determine the potential mechanistic difference that could be responsible for the differing 

















Study subjects (n=5) were patients who underwent allogeneic peripheral blood 
stem cell transplants at West Virginia University’s Mary Babb Randolph Cancer Center, 
Morgantown, West Virginia. Informed consent was obtained from participants after the 
nature and possible consequences of the study had been fully explained according to 
West Virginia University’s Internal Review Board guidelines. A volume of ~20 mL 
peripheral blood was collected weekly through day 100 post transplant, via venipuncture 
from hematopoietic stem cell transplant patients, into an acid citrate dextrose 
VACUTAINER™ blood collection tube (Becton Dickinson, Franklin Lakes, NJ, USA). 
Buffy coat layers were isolated via centrifugation at 3300 rcf for 10 minutes. 




In vitro experiments were performed using the Jurkat human T-cell line (clone 
E6-1) (American Type Culture Collection, Rockville, MD). Cells were cultured at a 
density of 4x105 cells/mL in RPMI-1640 (HyClone, Logan, UT) supplemented with 10% 
heat-inactivated fetal calf serum (FCS) (Hyclone), 2 mM L-glutamine (BioWhittaker, 
Walkersville, MD), penicillin (100U/mL) (BioWhittaker), streptomycin (100ug/mL) 
(BioWhittaker), and 2-mercaptoethanol (0.049 mM) (Sigma Chemical Co., St. Louis, 




For human studies, patients were treated with CSA and/or FK506 according to 
established treatment protocols at the West Virginia University Mary Babb Randolph 
Cancer Center’s Blood and Marrow Transplant Program. CSA therapy is classically 
utilized when the recipient has a matched related donor (MRD) and FK506 therapy is 
instituted when the recipient has a matched unrelated donor (MUD) or is unresponsive 
post-transplant to CSA therapy. CSA and/or FK506 treatment started one day before 
transplant (d-1) and continued throughout the study period. Patients were monitored bi-
weekly for CSA and FK506 serum concentrations. Patient dosages were adjusted, as 
87 
necessary, to be within the preferred protocol serum concentrations of 200+/-20 ng/mL 
for CSA and 7-12 ng/mL for FK506. 
For in vitro cell culture studies, CSA (Bedford Laboratories, Bedford, OH) and 
FK506 (Fujisawa Healthcare, Inc., Deerfield, IL) were diluted in prepared media 
(previously described) to obtain 1/2x , 1x, and 2x of the target therapeutic dose. This 
resulted in the following concentrations: for CSA, 100ng/mL, 200ng/mL, and 400ng/mL; 
for FK506, 5ng/mL, 10ng/mL, and 20ng/mL. Cells were pretreated +/- CSA or FK506 for 
30 minutes at 37oC followed by addition of the stimulating agents phorbol 12-myristate 
acetate (PMA) (Sigma Chemical Co.) and A23187 calcium ionophore (Sigma Chemical 




Total RNA was isolated from 20-40 x 106 white blood cells using TRIzol® Reagent 
according to the manufacturer’s directions (Ambion, Austin, TX, USA). RNA was 
dissolved in ultra-PURE™ Distilled DNAse and RNAse free water (Invitrogen 
Corporation, Carlsbad, CA, USA). DNase treatment was performed on isolated RNA 
according to the manufacturer’s recommendations using DNA-free™ (Ambion). RNA 
purity and concentration was determined by standard 260nm:280nm spectrophotometric 
analysis using a Genesis 10UV Spectronic Unicam (Spectronic Instruments, Rochester, 




One Step RT-PCR was performed using the QuantiTect™ Probe RT-PCR kit 
(Qiagen, Valencia, CA, USA). Recommended reaction mixtures were scaled down to a 
total reaction volume of 20 µL using 0.04 µg RNA with the following primer and probe 
concentrations: 0.4 µM TCRBV primer (Biosource International, Camarillo, CA, USA), 
0.4 µM TCRBC primer (Biosource International), and 0.2 µM TCRBC TaqMan® probe, 5’ 
6-FAM, 3’ BHQ™-1 (Integrated DNA Technologies, Inc., Coralville, IA, USA). The 
method, including primer and probe sequences, was as previously described (Brewer 
and Ericson, J. Immunol. Method, in press). In brief, 18SrRNA standardization reactions 
were performed in parallel using 0.4 µM each of sense and anti-sense primers 
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(Biosource International) and 0.2 µM 18S rRNA  TaqMan® probe, 5’ 6-FAM, 3’ BHQ™-
1 (Integrated DNA Technologies, Inc.). An iCycler™ (BioRad Laboratories, Hercules, 
CA, USA) was used for the RT and amplification cycles. RT was performed at 50oC for 
60 minutes, max ramp speed, followed by an initial Taq activation step of 15 minutes at 
95oC, max ramp speed. A TouchDown PCR approach 20 was used with the following 
cycling conditions: denaturation for 15 seconds at 95oC, max ramp speed, annealing for 
30 seconds starting at 70oC decreasing by 2oC for 10 repeats, max ramp speed, and 
extension for 40 seconds at 72oC, min ramp speed. After this TouchDown of the 
annealing temperature, 50 cycles were performed as follows with the optical data 
collection occurring at the extension step: 15 seconds at 95oC (max ramp speed), 30 
seconds at 52oC (max ramp speed), and 40 seconds at 60oC (min ramp speed). 
Reactions were held at 4oC upon the conclusion of the run. Cycle threshold (Ct) values, 
or the cycle at which fluorescent amplification readings exceed background level, were 
determined using iCycler™ iQ Optical System Software Version 3.0a (BioRad 
Laboratories, Hercules, CA, USA). The primer sets utilized in this study have been 
previously shown to yield Ct values that are directly proportional to the amount of 





3x106 Jurkat cells (at a density of 4x105 cells/mL) were plated per treatment 
condition. At time points 24 hours, 36 hours, and 48 hours, 1x106 cells were removed 
from the culture. Viability was determined by trypan blue exclusion (Gibco Laboratories, 
Grand Island, NY) and 7-AAD incorporation (BD Pharmingen, San Diego, CA). 7-AAD 
incorporation was performed according to the manufacturer’s instructions. Stained cells 
were resuspended in 200 µL 1% paraformaldehyde solution. 30,000 total events were 
collected per sample using a Becton Dickinson FACSCalibur™ that was calibrated using 
Calibrite Beads™ and FACSCOMP™ software (Becton Dickinson, Franklin Lakes, NJ). 
Acquisition of data was performed using CellQuest™ Pro software (Becton Dickinson). 
Data was analyzed using Windows Multiple Document Interface (WinMDI) version 2.8 
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(Joseph Trotter, The Scripps Research Institute, http://facs.scripps.edu/software.html 
[14 December 2001]).  
 
Cell proliferation assay 
 
Cell proliferation was monitored by labeling cells prior to culture using the 
Molecular Probes Vybrant™ CFDA SE Cell Tracer Kit (Molecular Probes, Inc., Eugene, 
OR) according to manufacturer’s instructions. 3x106 CFSE labeled Jurkat cells (at a 
density of 4x105 cells/mL) were plated per treatment condition. At time points, 24 hours, 
36 hours, and 48 hours, 1x106 cells were removed from the culture, spun down and 
washed in 1x PBS prior to being resuspend in 200uL 1% paraformaldehyde. Cells were 
analyzed using a Becton Dickinson FACSCalibur™ that was calibrated using Calibrite 
Beads™ and FACSCOMP™ software (Becton Dickinson). Acquisition of data was 
performed using CellQuest™ Pro software (Becton Dickinson). Results were analyzed 
using ModFit LT™ software (Verity Software House, Topsham, ME). A total of 30,000 




3x106 Jurkat cells (at a density of 4x105 cells/mL) were plated per treatment 
condition. At time points, 24 hours, 36 hours, and 48 hours, 1x106 cells were removed 
from the culture and spun down. Supernatant was harvested and used to determine IL-2 
production using the BD OptEIA™ Human IL-2 ELISA Kit II (BD Biosciences, San Diego, 
CA) according to manufacturer’s instructions. Colorimetric reactions were read on a 
Labsystems Multiskan MCC/340 microplate reader (Molecular Devices Corporation, 
Sunnyvale, CA) and data was analyzed using the Genesis Lite Version 3.0 software 




The Calcineurin Cellular Activity Assay Kit (Calbiochem, San Diego, CA) was 
used to determine the activity of calcineurin under various treatment condition. 4.5x106 
Jurkat cells (at a density of 4x105 cells/mL) were pretreated with doses of CSA or 
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FK506 for 30 minutes at 37oC followed by stimulation with PMA and A23187 (as 
described above) for 0 minutes, 5 minutes, 10 minutes, 20 minutes, or 30 minutes. Cells 
were harvested, washed, and lysed according to kit instructions. The harvested “high 
speed supernatant” was desalted using Econo-Pac® 10DG Columns (Bio-Rad 
Laboratories). Trace contaminating salts were determined to be absent from the 
desalted samples using the GREEN™ reagent as described in the assay kit. Desalted 
“high speed supernatants” were assayed for calcineurin phosphatase activity as 
described by the manufacturer’s instructions.  Colorimetric reactions were read on a 
Labsystems Multiskan MCC/340 microplate reader (Molecular Devices Corporation) and 





For TCRBV alterations in response to CSA and FK506, bivariate fit statistical 
analysis was employed. One-way analysis of variance with Tukey’s post-hoc test was 





Cyclosporin A and FK506 differentially impact T cells bearing specific T cell 
receptors. 
 
In order to assess any alterations in the T cell receptor beta variable (TCRBV) 
repertoire associated with the administration of cyclosporin A (CSA) or  
Table 1: In vivo TCRBV expression changes in response to increases in FK506 and CSA 
dosages. 
Opposite trends were observed for the changes in TCRBV repertoire expression in response to 
the immunosuppressive agents FK506 and CSA. Results shown are derived from analysis of 5 
patients, 11-14 time points/patient totaling 70 separate observations, each performed in triplicate. 
Reported p-values are indicative of statistical significance with a confidence interval of at least 
95%, or p<0.05.  
 
tacrolimus (FK506), human T cells were isolated from allogeneic peripheral 
(hematopoietic) stem cell transplant patients weekly up to 100 days post transplant. We 
hypothesized that both CSA and FK506 would have a “global” immunosuppressive 
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effect on the T cells within the hematopoietic stem cell recipients. Analysis of the 
TCRBV repertoire, however, demonstrated polarized responses of T cells to these two 
agents (Table 1). When TCRBV expression was analyzed in response to FK506, a 
predominant suppression was observed in its effects on T cells bearing specific 
receptors, specifically TCRBV1-6, 11-16, and 20-23. However, when samples were 
analyzed for the effect induced by CSA, an increase in the expression of TCRBV4-6, 
11-13, 15, 16, and 21 was observed. The in vivo concentration of CSA and FK506 can 
be impacted by various factors. Calcium channel blockers, anti-fungal agents, 
antibiotics, and anti-inflammatory drugs are among the agents known to potentially 
increase the serum concentrations of CSA and FK506 (according to manufacturer). 
Anticonvulsants, grapefruit, and dietary supplements, such as St. John’s Wort, may 
have the opposite effect and decrease serum concentrations of CSA and FK506 
(according to manufacturer). To ensure that such metabolic alterations were not causing 
artificial changes in the expression of the TCRBV repertoire, serum concentrations of 
CSA and FK506 were also analyzed for their impact on the TCRBV expression levels. 
The analyses using either the actual dosage level (Table 1) or the serum level (data not 
shown) yielded similar results.   
 
Cyclosporin A and FK506 affect on cell viability. 
 
It is possible that the different TCRBV usage between CSA and FK506 in vivo 
was due to a differential effect of the two agents on T cell viability. In order to assess 
this potential difference in viability in vitro studies 
were performed using the T–cell derived Jurkat 
cell line. Jurkat cells were pretreated with a range 
of concentrations of CSA (0-400ng/mL) or FK506 
(0-20ng/mL) prior to stimulation with PMA and 
A23187 and then cultured for 24 hr, 36 hr, or 48 
hr at which time 7-AAD staining was done to 
access viability. As depicted in Figure 2, 
significant differences were not obtained in cell 
viability, despite the presence of CSA or FK506.  
Figure 2: Effects of CSA and FK506 on 
Jurkat cell viability as measured by 7-AAD 
exclusion. 
Results depicted are the means of two independent experiments. Abbreviations: no Rx, no 
addition of immunosuppressive agent; CSA, plus the addition of cyclosporin A; FK506, plus the 




Similar results were seen when cells were pretreated with any of the following 
concentrations of immune suppressive agents: one-half therapeutic dose (CSA: 
100ng/mL, FK506: 5 ng/mL), therapeutic dose (CSA: 200 ng/mL, FK506: 10 ng/mL), or 
twice the therapeutic dose (CSA: 400 ng/mL, FK506: 20 ng/mL), or when viability was 
assessed after 24 hours or 48 hours of culture. At 24 hr, 36 hr, and 48 hr, a trend of 
higher cell death was observed with the pretreatment of both the therapeutic and twice 
the therapeutic doses of CSA compared to FK506. These difference, however, were not 
found to be statistically significant. Similar results were also observed when viability was 
assessed by trypan blue exclusion. 
 
Treatment with Cyclosporin A and FK506 do not alter the proliferation of Jurkat 
cells. 
 
With viability not noticeably altered by treatment with either CSA or FK506, the 
proliferative ability of the treated cells was examined next.  
Figure 3: Effects of CSA and FK506 on Jurkat cell proliferation as determined by CFSE cellular 
membrane labeling. 
The proliferative index, or the sum of the cells in all generations divided by the computed number of 
original parent cells present at the start of the experiment, was determined for all samples from two 
independent experiments with their means +/- SEM indicated. The proliferative index is a measure 
of the increase in cell number in the culture over the experimental period. No statistically significant 
differences were observed for proliferation experiments. Abbreviations: no Rx, no addition of 
immunosuppressive agent; CSA, plus the addition of cyclosporin A; FK506, plus the addition of 
FK506. Experiments depicted are for target therapeutic doses of CSA (200ng/mL) and FK506 
(10ng/mL). 
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The proliferative index is a calculated measurement of the increase observed in 
the culture’s cell number over the course of the experiment. As depicted in Figure 3, no 
statistically significant difference in cellular proliferation was observed when cells were 
treated with either CSA or FK506. Additionally, no statistically significant differences 
were detected when the cells were treated with a range of concentrations of CSA or 
FK506 (one-half therapeutic dose, therapeutic dose, or twice the therapeutic dose) or 
when cells were permitted to proliferate for 24, 36, or 48 hours. 
 
Cyclosporin A and FK506 inhibit IL-2 production in Jurkat cells. 
 
CSA and FK506 are known to inhibit IL-2 production by T cells 13-16. While high 
IL-2 levels were produced by untreated 
(without the addition of CSA or FK506) 
stimulated Jurkat cells, significant 
differences were observed between the 
levels of IL-2 produced by treated and 
untreated samples, regardless of the 
concentration of the agents used (one-
half therapeutic dose, therapeutic dose 
(Figure 4), or twice the therapeutic dose) 
or the length of the culture period (24, 36, 
or 48 hours). In addition, there was no 
statistically significant difference found in 
the suppression of IL-2 production 
between CSA and FK506 treatments. 
Both agents were found to inhibit IL-2 
production equally and were determined 
to not interfere with the in vitro IL-2 
detection assay. 
Figure 4: Effects of CSA and FK506 on IL-2 secretion 
by Jurkat cells as measured by ELISA. 
Data is representative of the means of two 
independent experiments +/- SEM. Statistical 
significances are noted.  Dotted lines indicate assay 
limit of detection. Abbreviations: no Rx, no addition of 
immunosuppressive agent; CSA, plus the addition of 
cyclosporin A; FK506, plus the addition of FK506. 
Experiments depicted are for target therapeutic 






Calcineurin activity is inhibited equally by both CSA and FK506. 
 
The inhibition of IL-2 production by 
both CSA and FK506 is known to occur by 
the binding of these agents to their binding 
partners cyclophilin and FK-binding 
protein, respectively, and their subsequent 
inhibition of calcineurin 7-12. Therefore, the 
activity of calcineurin in Jurkat cells treated 
with CSA or FK506 was measured in vitro. 
Jurkat cells were treated with the 
therapeutic doses of CSA and FK506 and 
stimulated with PMA and A23187 calcium 
ionophore for 5, 10, 20, or 30 minutes prior 
to cellular protein collection. As 
anticipated, cells treated with either CSA or 
FK506 resulted in a significant decrease in 
the activity of calcineurin compared to 
untreated control cells (Figure 5). 
Significant differences, however, were only observed at the five-minute time point and 
no significant difference was ever observed between CSA and FK506. Additionally, it 
was determined that neither agent interfered with the detection of the in vitro calcineurin 
activity assay. 
Figure 5: Effects of CSA and FK506 on calcineurin
activity in Jurkat cells. 
Data is representative of the means of two 
independent experiments +/- SEM. Statistical 
significances are noted.  Dotted lines indicate 
assay limit of detection. Abbreviations: no Rx, no 
addition of immunosuppressive agent; CSA, plus 
the addition of cyclosporin A; FK506, plus the 
addition of FK506. Experiments depicted are for 












Despite the fact that both CSA and FK506 inhibit IL-2 production by T cells, 
different effects were observed on the T cell receptor repertoire in the presence of these 
immunosuppressive agents in peripheral blood samples from patients undergoing 
allogeneic peripheral blood stem cell transplant. This observation, however, cannot be 
attributed to differences in the viability, proliferation, IL-2 production, or calcineurin 
activity of Jurkat cells treated with CSA versus FK506 in vitro.  
Since the in vivo setting is rather complex in experimental variables, we chose to 
perform in vitro experiments using the Jurkat human T-cell line. T helper cells have 
been documented to be the main target of CSA and FK506 (according to 
manufacturers), and this was an additional reason for using Jurkat cells (CD4+) in in 
vitro experiments. An additional advantage to using this cell line is that Jurkat cells 
express TCRBV8 19, a TCR that showed varied responses to CSA compared to FK506 
(Table 1). A decrease in TCRBV8 was seen with CSA whereas no significant response 
was observed with FK506 treatment.   
Two previous reports detailed the changes in the expression of TCRBV8 in 
response to CSA therapy. Fischer et al., described an increase in TCRBV8.5 in mice 
following administration of CSA therapy 21 and Severino et al., reported an increase in 
the expression of TCRBV8 in CSA-induced murine syngeneic graft-versus-host disease 
22. Although it has been determined that great homology exists between the TCRBV 
families in mice and humans 23, there is no report of TCRBV8.5 in humans 24, making 
these specific murine studies difficult to directly compare to our study. They do, 
however, suggest that CSA can exert differed effects on cells carrying a specific 
TCRBV. 
While the inhibition of IL-2 production through the blocking of calcineurin is the 
accepted mechanism of action for both CSA and FK506 13-16, a report by Marton et al., 
in yeast cells has alluded to the possible existence of a calcineurin-independent 
pathway for FK506-mediated effects 25. Using a yeast model and various mutants, they 
demonstrated that many of the GCN-4 regulated genes were induced by exposure to 
FK506. GCN-4, a c-Jun/c-Fos homolog, is a eukaryotic transcriptional activator protein 
that is primarily responsible for the regulation of biosynthetic genes in Saccharomyces 
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cerevisiae 26-29. Although different model systems, both humans and yeast are 
eukaryotic and a crossover in this alternative pathway may exist. There is also evidence 
that there is different transcriptional control in humans depending upon the TCRBV 
usage, with factors such as the promoter and non-coding (spacer) regions contributing 
to these differences 30-35.  
Our results argue that a secondary mechanism of action for the altered TCRBV 
repertoire must exist for these immunosuppressive agents as none of the above 
mentioned parameters, including calcineurin activity, IL-2 production, cell viability and 
proliferation, exhibited differing effects in response to CSA and FK506 treatments. While 
the possibility still exists due to our small sample size, we do not believe that these 
results are attributed to donor variability as results reported were observed across the 
population of patient/donor pairs, not unique to any single case. Future investigation into 
alternative mechanisms may yield a clearer understanding of the cellular events 
responsible for the varying effect on T cells by the related immunosuppressive agents 
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The overall goal of this investigation was to identify and study the role of specific 
T lymphocytes following human hematopoietic stem cell (HSC) transplant. Current 
literature has stressed the importance of T lymphocytes in this setting but has thus far 
focused on the identification of specific families of T lymphocytes as it pertains to the 
occurrence of graft-versus-host disease (GVHD). Several novel findings have emerged 
from our investigation: (1) a panel of oligonucleotides has been developed to accurately 
and efficiently detect expression of all known human TCRBV regions, (2) specific 
TCRBV families are associated with reactivation of cytomegalovirus (CMV) post HSC 
transplant with many of these same TCRBV families also being associated with the 
occurrence of GVHD, (3) the TCRBV repertoire engrafts in the recipient with a profile 
more similar to that found in the donor as opposed to that found in the recipient prior to 
transplant, and (4) the similar immunosuppressive agents, cyclosporin A (CSA) and 
tacrolimus (FK506), differentially alter the TCRBV repertoire with their administration.   
Prior investigations have used the TCRBV regions to identify specific T cells 
involved in various settings, such as with GVHD. While our study had initially planned 
on utilizing prior existing technology to further investigate the role of T lymphocytes in 
the post HSC transplant environment, we were unable to locate a method that 
accurately examined all of the TCRBV genes. To address this, we relied on the TCR 
gene classification system instituted by the World Health Organization. Using various 
sequence databases and strict primer sequence specifications, we were able to develop 
a panel of primers that could be used to accurately and efficiently identify all 91 alleles 
of the human TCRBV region. Using these primers and sequence specific (TaqMan® 
probe) real-time PCR detection, we demonstrated that our system was not only specific 
but also efficient and comparable to TCRBV protein expression profiles. The importance 
of this technology was realized and has since been protected by both U.S. and foreign 





Once a method was available to accurately identify T cells based upon their 
TCRBV expression, we wanted to apply this technology to our specific area of interest, 
the post HSC transplant setting. Many prior investigations using human HSC transplant 
patients have focused on identifying the T cells associated with GVHD. These studies 
relied on “snapshot” sampling, for example collecting a sample early post transplant and 
at the time of GVHD diagnosis. Many of these studies also aimed to determine if there 
was an association of specific T cells in the peripheral blood (PB) and in the GVHD 
tissue lesion, the lesion frequently being a skin biopsy. In these studies, though, such 
an association was rarely seen. We believed one explanation for the lack of association 
of PB and GVHD lesion TCR repertoires was due to the fact that PB and tissue samples 
were drawn simultaneously. This timing of sample procurement would not accounting 
for the fact that (1) the development of GVHD is not an instantaneous process and, (2) 
the T cells expanded in the PB would traffic to the lesion after expansion, resulting in an 
efflux of these cells from the PB and an influx of these cells into the lesion. In our study, 
we instituted a serial sampling schedule where baseline samples were collected from 
both the donor and recipient prior to transplant, with recipient sample collection 
continuing on a weekly basis post HSC transplant, up to day 100. Day 100 was chosen 
as our final time point since acute GVHD, by definition, occurs no later than day 100 
post transplant. The chronic form of the disease may not appear for several months to 
years after transplant, yielding a sampling schedule not conducive to our time frame. 
While our initial plans of obtaining a GVHD lesion sample at time of diagnosis was not 
fulfilled, we were able to collect PB samples from our study patients on a regular basis. 
This led us to analyze not only what TCRBV families were involved in GVHD but also 









Our HSC transplant center here at West Virginia University has frequently 
observed the association of CMV reactivation post transplant and the subsequent 
development of GVHD. Although there are several studies that support the notion that a 
link does indeed exist between CMV and GVHD, no such study has looked at the 
similarity in TCRBV expression with these two complications post HSC transplant. We 
not only determined which TCRBV families were associated with CMV reactivation in 
this setting, but were also able to draw parallels between many of these TCRBV families 
and those also associated with GVHD. Further, many of the families we determined to 
be associated with CMV reactivation have been previously shown to be CMV reactive in 
what are considered otherwise healthy human donors. Not only is our study the first to 
identify those TCRBV families associated with CMV reactivation post HSC transplant, 
we were also the first to show an overlap in the TCRBV families associated with CMV 
and GVHD. 
Since we had serial TCRBV analysis of our patients, we utilized our data sets to 
determine if the transplanted donor HSCs developed with a phenotype more 
reminiscent of that found in the recipient prior to transplant or with greater similarity to 
the mature profile found in the donor. We expected that the influence of the recipient’s 
environment on these developing HSC would consequently lead to the development of 
a TCRBV repertoire more reminiscent of that found in the recipient prior to transplant. 
However, our samples exhibited an engraftment profile with a greater correlation to that 
found in the donor prior to transplant compared to that initially found in the recipient. 
While we had a small sample population (n=4) these are the first results we can find to 
investigate this question. Furthermore, we do not believe these results are attributable 
to analysis of mature donor T cells initially found within the graft as the patients that 
exhibited this trend all received Campath-1H therapy that specifically targets the 
destruction of any residual mature donor T cells found within the graft. The one patient 
that exhibited a greater correlation to herself than to that found in the donor at the 
conclusion of the study was the sole patient in our population that did not receive the 
Campath-1H regimen, but received an alternate myeloblative regimen. These results 
are preliminary but do inspire further thoughts into the contribution of the recipient 
environment on the development of the transplanted donor cells. 
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As a consequence of serial time point analysis and the treatment of all of our 
study participants with immunosuppressive agents, we observed that the highly similar 
immunosuppressive agents CSA and FK506, which are both calcineurin inhibitors, had 
polarized effects on the TCRBV repertoire. FK506 administration resulted in an overall 
suppression of TCRBV expression while the opposite effect was observed with CSA 
therapy. Interesting to this observation is the fact that in the HSC transplant setting, 
FK506 administration is customarily reserved for situations in which greater genetic 
disparity exists between the recipient and donor, with CSA administration typically being 
utilized for those transplants with fewer mismatch-related complications anticipated. 
Potentially our observation could help to explain the immunology behind such 
pharmacological strategies. To try to determine if there was some facet of the known 
immunosuppression mechanism of these two agents responsible for contributing to our 
observed difference, we examined the effect of these two agents in vitro using the 
human Jurkat T cell line. We determined that while both of these agents did decrease 
the activity of calcineurin and, subsequently inhibited the production of IL-2, they did so 
equally well. 
Taken together, we feel we have contributed to the understanding of the role of 
specific T cells in the post HSC transplant environment. While our sample population 
was large compared to prior similar investigations, we hope that future studies will 
confirm our results using larger sample populations. Not only has our work contributed 
to the field of HSC transplantation but also to the field of immunology as a whole. Our 
TCRBV expression technology vastly improves upon that which existed in the field prior 
to our entry, and we anticipate the application of our technology to many areas of 
immunological interest, including the usage of specific TCRBV families during infectious 
disease, autoimmune disease, graft rejection, and even cancer therapy and graft-
versus-leukemia effect. Future work will hopefully elucidate a greater understanding of 
the association of CMV reactivation and GVHD with the identification of specific 
antigens driving these T cell responses. The possible existence of a secondary 
mechanism of action for CSA and FK506 will also be investigated in the future and will 
help to encourage a re-thinking of present treatment strategies. Should all patients not 
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be given FK506 as opposed to the present directing of patients into treatment groups 
based upon the relation of the donor?   
In conclusion, one of the most interesting facets of this project was the identity it 
took over time. As data was generated and the novelties of patient sampling became 
more apparent, areas that were initially anticipated to be of less interest became 
increasingly curious and of interest. It reasons that one of the facets to being a good 
scientist is to set aside pre-conceived notions and approach the data with neutrality. By 
these means truths are discovered and the field of science marches onward. After all, 






Amplification efficiency analysis 
 
Amplification efficiency analysis for TCRBV primers was determined using the following 
formula: 
 
Efficiency (E) = (10-1/slope)-1 
Where the slope is determined by plotting the Ct value (Y-axis) vs log [cDNA] (X-axis) 
using 10-fold dilutions of template  
 
Example of equation usage: 
slope of amplification plot is determined to be -3.59 
E = (10-1/-3.59)-1 
E=10 0.28-1 
E=1.90-1 
E=0.90, or 90% efficient 
 
Reference: Rasmussen, R. (2001) Quantification on the LightCycler. In Meuer, S., 
Wittwer, C. and Nakagawara, K. (eds), Rapid Cycle Real-time PCR, Methods and 
Applications. Springer Press, Heidelberg, pp. 21-34. 
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IOTest™ Beta Mark TCR VB Repertoire Kit 
 
The IOTest™ Beta Mark TCR VB Repertoire Kit (Beckman Coulter, Inc., 
Fullerton, CA) was used for TCRBV protein expression analysis. Samples were 
prepared according to the manufacturer’s directions using 5 x 105 buffy coat white blood 
cells per sample, prepared as previously described. To identify CD3+ cells for TCR 
analysis an anti-CD3 PC5 antibody and an IgG1 PC5 isotype antibody, each at a 
volume of 10µl/sample (Beckman Coulter, Inc.) were used as described in the IOTest™ 
kit specifications. Stained samples were then washed in 1X PBS prior to fixation in 500 
µl of 1% paraformaldehyde. All prepared samples were analyzed by flow cytometric 
analysis using a FACScan (Becton Dickinson, Franklin Lakes, NJ), which had been 
calibrated using three color Calibrite Beads (Becton Dickinson) and FACSCOMP 
software (Becton Dickinson). A total of 5,000 live-gated CD3+ cells were collected for 
analysis of each IOTest™ TCR BV expression sample. SSC and FSC data were 
acquired in the linear mode and the FL1, FL2, and FL3 parameters were collected 
logarithmically. Data analysis was performed using Windows Multiple Document 
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